<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="100" offset="0" totalResults="132178"><SearchResults><Trial Id="321008"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Inactivated vaccine</Action><Action>Metastasis inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Jinan University (Guangdong)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2017-11-30T00:00:00Z</DateStart><Identifiers><Identifier>COLORECTAL CANCER MV</Identifier><Identifier>NCT03357276</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mix vaccine (sc, colorectal cancer), Fuda Cancer Hospital/Jinan University alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Group 1: in this group, the patients will receive mix vaccine (sc, colorectal &lt;b&gt;cancer&lt;/b&gt;), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan University. The check... the patient refuses standard therapies after &lt;b&gt;cancer&lt;/b&gt; recurrence Body tumor 1 to 6, the maximum tumor length&amp;lt; 2 cm KPS &amp;gt;/= 70, lifespan&amp;gt; 6 months Platelet count...to evaluate the safety and efficacy of mix vaccine (sc, colorectal &lt;b&gt;cancer&lt;/b&gt;), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan University to small metastasis of colorectal &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of T-cells</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS) - Assessment of overall survival at 3 years</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Mix Vaccine for Metastatic Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Recurrent/Relapsed Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen, MD, PhD</Name></ContactNames></Trial><Trial Id="339289"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN COLORECTAL CANCER</Identifier><Identifier>NCT03524274</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>center, the investigators will be planing to recruit for 90 patients with advanced colorectal &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients...anti-MUC1 BiTE cytokine induced killer cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical together with cryotherapy. The maximum tumor length &amp;gt;/= 2 cm, cool down... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment><PatientSegment>Colorectal tumor - Subjects with resectable colorectal cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="336775"><Indications><Indication>Metastatic lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2021-03-27T00:00:00Z</DateEnd><DateStart>2018-03-27T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN LUNG CANCER</Identifier><Identifier>NCT03501056</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators plan to recruit for 90 patients with advanced lung &lt;b&gt;cancer&lt;/b&gt;. This study consist of three treatment arms: Arm 1 (cryotherapy): patients with the...anti-CD3/MUC1 ; anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical) will be administered. Arm 3 (no Intervention...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma„ÄÅmyeloma,and patients are using immunosuppressant Systemic</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 years</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Evaluation by MRI/CT scan</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-Induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Resectable/Operable Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-27T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="339277"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN BREAST CANCER</Identifier><Identifier>NCT03524261</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators will plan to recruit for 90 patients with advanced breast &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant... Age 18 to 75 years The patient is diagnosed as advanced breast &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10 mm</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="337607"><Indications><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2021-04-12T00:00:00Z</DateEnd><DateStart>2018-04-12T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN PANCREATIC CANCER</Identifier><Identifier>NCT03509298</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators will plan to recruit 90 patients with advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, and all patients are divided into three groups. One group will receive cryotherapy...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma,and patients are using immunosuppressant Systemic... Age 18 to 75 years old The patient is diagnosed as advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="342813"><Indications><Indication>Metastatic stomach cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN GASTRIC CANCER</Identifier><Identifier>NCT03554395</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators plan to recruit for 90 patients with advanced gastric &lt;b&gt;cancer&lt;/b&gt;,and all patients are divided into three groups: one group will receive...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant... Age 18 to 75 years old The patient is diagnosed as advanced gastric &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Relapse/Recurrence - Assessment of relapse rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Resectable Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage IV Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Stomach tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="341183"><Indications><Indication>Metastatic renal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2021-04-10T00:00:00Z</DateEnd><DateStart>2018-04-10T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN KIDNEY CANCER</Identifier><Identifier>NCT03540199</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators will recruit 90 patients with advanced kidney &lt;b&gt;cancer&lt;/b&gt;, and all patients are divided into three groups: Group 1(cryotherapy): patients with maximum...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma and patients are using immunosuppressant Systemic... Age18 to 75 years old The patient is diagnosed as advanced kidney &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10mm</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other Measures of Response - Assessment of best response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other/Unspecified Efficacy Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of duration of objective/overall response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="34162"><Indications><Indication>Bladder cancer</Indication><Indication>Cancer</Indication><Indication>Esophagus tumor</Indication><Indication>Hormone refractory prostate cancer</Indication><Indication>Non-small-cell lung cancer</Indication><Indication>Sarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal high velocity particle formulation</Technology></Technologies><CompaniesCollaborator><Company>Columbia University</Company><Company>MD Anderson Cancer Center</Company><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-24T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-0013</Identifier><Identifier>LUD2002-006</Identifier><Identifier>NCT00199849</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>LAGE-1 antigen would be assigned to cohorts. NY-ESO-1 Plasmid DNA (pPJV7611) &lt;b&gt;cancer&lt;/b&gt; vaccine would be administered by PMED at a pressure of 500 psi using the XR...skin &lt;b&gt;cancer&lt;/b&gt;, cervical carcinoma in situ and incidental prostate &lt;b&gt;cancer&lt;/b&gt; on radical cystoprostatectomy specimen Mental impairment, in the opinion of...breast &lt;b&gt;cancer&lt;/b&gt;, bladder &lt;b&gt;cancer&lt;/b&gt;, hepatocellular &lt;b&gt;cancer&lt;/b&gt;, synovial sarcoma, leiomyosarcoma, head and neck, lung &lt;b&gt;cancer&lt;/b&gt;, esophageal, ovarian, neuroblastoma</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Antibodies</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Chemotherapy Induced Toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of immunological markers</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of subject withdrawals</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of antibody titers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of cellular response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of progressive disease</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of treatment emergent adverse events</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Metastatic Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage IV Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Neuroblastoma - Subjects with INSS Stage 4 Neuroblastoma</PatientSegment><PatientSegment>Neuroblastoma - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Cancer Resistant or Refractory to Non-Platinum Therapies</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Leiomyosarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Synovial Sarcoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Nasser K Altorki, MD</Name><Name>Padmanee Sharma, MD PhD</Name></ContactNames></Trial><Trial Id="321009"><Indications><Indication>Metastatic renal cell carcinoma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Metastasis inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Jinan University (Guangdong)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2017-11-30T00:00:00Z</DateStart><Identifiers><Identifier>KIDNEY CANCER MV</Identifier><Identifier>NCT03357289</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mix vaccine (sc, renal tumor), Fuda Cancer Hospital/Jinan University alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>survival (PFS) and overall survival (OS). Group 1: in this group, the patients will receive mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan...guidelines or the patient refuses standard therapies after &lt;b&gt;cancer&lt;/b&gt; recurrence Body tumor 1 to 6, the maximum tumor length&amp;lt; 2 cm KPS &amp;gt;/= 70, lifespan &amp;gt; 6 months...is to evaluate the safety and efficacy of mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan University to small metastasis of kidney &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Immune Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 months</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Hematological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - MRI assessment/changes</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - PET/CT scan assessment/changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Mix Vaccine for Metastatic Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Recurrent/ Relapsed Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease - Subjects resistant/refractory to standard treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen, MD, PhD</Name></ContactNames></Trial><Trial Id="338912"><Indications><Indication>Bladder cancer</Indication><Indication>Transitional cell carcinoma</Indication></Indications><CompaniesCollaborator><Company>Johns Hopkins University</Company><Company>National Institutes of Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-04T00:00:00Z</DateChangeLast><DateEnd>2022-12-31T00:00:00Z</DateEnd><DateStart>2019-09-30T00:00:00Z</DateStart><Identifiers><Identifier>MCC-19574</Identifier><Identifier>NCT03517995</Identifier></Identifiers><InterventionsControlDisplay><Intervention>bladder cancer surgery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Prostaphane (Nutinov Labs, France) alone</Intervention><Intervention>bladder cancer surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>135</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The surgical procedure will be done...from when participants will be diagnosed with bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The...other &lt;b&gt;cancer&lt;/b&gt;, excluding non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; Any treatment for the bladder tumor other than intravesical therapy Prior treatment with</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of apoptosis</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Bladder cancer - Clinical Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Resectable Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Caspase-3 </BiomarkerName><BiomarkerName> DNA replication licensing factor MCM2 </BiomarkerName><BiomarkerName> Epoxide hydrolase 2 </BiomarkerName><BiomarkerName> Glucuronosyltransferase </BiomarkerName><BiomarkerName> NADP </BiomarkerName><BiomarkerName> Nuclear factor erythroid 2 related factor 2 </BiomarkerName><BiomarkerName> Transcription factor p65</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Cesar Ercole, M.D.</Name><Name>Kayoko Kennedy</Name><Name>Nagi Kumar, Ph.D</Name><Name>Nagi Kumar, Ph.D.</Name></ContactNames></Trial><Trial Id="240229"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-08-15T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER CAR-T 001</Identifier><Identifier>NCT02547961</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HER-2-targeting CAR T cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>breast &lt;b&gt;cancer&lt;/b&gt;. Autologous T cells would be gene-engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients would be... Chemotherapy refractory Her2 positive breast &lt;b&gt;cancer&lt;/b&gt; Relapsed patients after anti-Her2 using antibody or kinase inhibitor therapy Patients must be &amp;gt;/= 18 years... The purpose of this study was to evaluate the safety and efficacy of HER2-CAR-T cell infusion for advanced HER2 positive breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Chimeric Antigen Receptor-Modified T Cells for Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-08-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Niu, PhD</Name></ContactNames></Trial><Trial Id="226797"><Indications><Indication>Metastatic lung cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2017-03-24T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>LUNG CANCER CTC 001</Identifier><Identifier>NCT02412384</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Dendritic cell(DC)-cytokine-induced killers(CIK) alone</Intervention><Intervention>Flow cytometry (FCM) alone</Intervention><Intervention>RT-PCR alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>acid (EDTA)-blood would be drawn by vein puncture from patients with lung &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers would be used to evaluate... Patients with other primary tumor except lung &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 75 years Karnofsky performance status&amp;gt; 60 Diagnosis of lung &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor, nodes</Teaser><TrialCategories><Category>Biomarker identification</Category><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Early Stage Lung Cancer - Subjects with stage II lung cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="230016"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER CTC 001</Identifier><Identifier>NCT02450357</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cryosurgery alone</Intervention><Intervention>Flow cytometry (FCM) alone</Intervention><Intervention>RT-PCR alone</Intervention><Intervention>dendritic cell (DC)-cytokine-induced killers(CIK) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Subjects with ‚Ö°, ‚Ö¢, ‚Ö£ stage breast &lt;b&gt;cancer&lt;/b&gt; who come to Fuda Hospital for treatment would be grouped into four arms: Arm 1: control: would use Flow cytometry (FCM...acid (EDTA)-blood would be drawn by vein puncture from subjects with breast &lt;b&gt;cancer&lt;/b&gt; and healthy subjects 1 day before and 2 days after cryosurgery with or without... Patients with other primary tumor except lung &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Mononuclear leukocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="230038"><Indications><Indication>Metastatic prostate cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02450435</Identifier><Identifier>PROSTATIC CANCER CTC 001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Flow cytometry (FCM) alone</Intervention><Intervention>dendritic cell-cytokine-induced killers (DC-CIK) alone</Intervention><Intervention>reverse transcriptase polymerase chain reaction (RT-PCR) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>tetraacetic acid (EDTA) blood was drawn by vein puncture from patients with prostatic &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers will be used to... Patients with other primary tumor except prostatic &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...Age:18 to 75 Karnofsky performance status&amp;gt; 60 Diagnosis of prostatic &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage II Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage III Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="230054"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>COLORECTAL CANCER CTC 001</Identifier><Identifier>NCT02450422</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Flow cytometry (FCM) alone</Intervention><Intervention>dendritic cell-cytokine-induced killers (DC-CIK) alone</Intervention><Intervention>reverse transcriptase polymerase chain reaction (RT-PCR) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>acid (EDTA)-blood would be drawn by vein puncture from patients with colorectal &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers would be used to... Patients with other primary tumor except colorectal &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 75 years Karnofsky performance status&amp;gt; 60 Diagnosis of colorectal &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="113344"><Indications><Indication>Metastatic bladder cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Krankenhaus der Barmherzigen Br√ºder Wien</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2018-02-05T00:00:00Z</DateChangeLast><DateEnd>2013-02-28T00:00:00Z</DateEnd><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>Bladder Cancer-001</Identifier><Identifier>Bladder Cancer-001</Identifier><Identifier>NCT01801644</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>radical cystectomy alone</Intervention><Intervention>cisplatin plus gemcitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>with histologically confirmed clinical stage T2-T4a, N0-2 bladder &lt;b&gt;cancer&lt;/b&gt; would be included. After computed tomography (CT) scan of the thorax and abdomen plus magnetic resonance imaging ...would be assessed according to the National &lt;b&gt;Cancer&lt;/b&gt; Institute Common Toxicity Criteria (CTC, version 3.0)....malignancies (with the exception of excised cervical or basal skin or squamous-cell carcinoma) Non-transitional cell bladder &lt;b&gt;cancer&lt;/b&gt; Creatinine clearance&amp;lt; 60 ml/min</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Locally Advanced Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage I Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage II Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage III Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage IV Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Johannes Meran, M.D.</Name></ContactNames></Trial><Trial Id="288283"><Indications><Indication>Bladder cancer</Indication><Indication>Transitional cell carcinoma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravesical formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Medelis</Company><Company>The University Health Network</Company><Company>West Coast Clinical Trials</Company></CompaniesCollaborator><CompaniesSponsor><Company>Theralase Technologies Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2018-08-27T00:00:00Z</DateEnd><DateStart>2016-12-21T00:00:00Z</DateStart><Identifiers><Identifier>NCT03053635</Identifier><Identifier>TLD1433 Bladder Cancer PDT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>TLC-3200 alone</Intervention><Intervention>TLD-1433 alone</Intervention><Intervention>photodynamic therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>6</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>activated for approximately 30 min and bladder would be void to remove destroyed bladder &lt;b&gt;cancer&lt;/b&gt; cells [ 1924481 ], [ 1998572 ]. The laser technician worksheet must be...cervical &lt;b&gt;cancer&lt;/b&gt;. A history of prostate &lt;b&gt;cancer&lt;/b&gt; that was treated with definitive intent (surgically or through radiation therapy...intravesical photodynamic therapy (PDT) with TLD-1433 in patients with non-muscle invasive bladder &lt;b&gt;cancer&lt;/b&gt; (NMIBC) at high risk of progression [ 1783362 ], [ 1783335 ], [ 1784364</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Survival - Assessment of recurrence-free survival</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Resectable Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0a or non-invasive papillary carcinoma (Ta)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0is or carcinoma in situ (Tis)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease - Refractory to BCG therapy</PatientSegment><PatientSegment>Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with nontransitional cell Bladder cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Troponin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-08-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Girish Kulkarni, MD, PhD</Name><Name>Lothar Lilge Ph.D</Name><Name>Michael Nesbitt</Name></ContactNames></Trial><Trial Id="141057"><Indications><Indication>Ovary tumor</Indication></Indications><CompaniesSponsor><Company>CancerVac Ltd</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-06-24T00:00:00Z</DateChangeLast><DateStart>2004-07-19T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12605000442606</Identifier><Identifier>Ovarian Cancer cellular immunotherapy</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>M-FP cancer vaccine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would receive intradermal injection of autologous dendritic cells cultured ex vivo with M-FP &lt;b&gt;cancer&lt;/b&gt; vaccine consisted of a portion (VNTR Region) of the MUC 1 protein fused to glutathione-S-transferase (GST) and conjugated to polymannose... The purpose was to study cellular immunotherapy on CA-125 response with M-FP &lt;b&gt;cancer&lt;/b&gt; vaccine in patients [ 1441135 ].</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of CA-125 level</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of CA-125/serological response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Tumor Related Parameters - Assessment of tumor stabilization rate</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase II Trial of Cellular Immunotherapy On CA-125 Response With M-FP Cancer Vaccine In Patients With Epithelial Ovarian Carcinoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Ovarian Cancer Subjects with CA-125 Expression</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Effie Skrinos</Name><Name>Emma Ball</Name></ContactNames></Trial><Trial Id="239006"><Indications><Indication>Lung tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-08-02T00:00:00Z</DateChangeLast><DateEnd>2016-08-31T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>LUNG CANCER HEPASPHERE</Identifier><Identifier>NCT02523404</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HepaSphere alone</Intervention><Intervention>digital subtraction angiography alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>receive HepaSphere interventional therapy using digital subtraction angiography (DSA) for lung &lt;b&gt;cancer&lt;/b&gt;. Arm 2 (placebo): patients would receive &amp;nbsp;traditional&amp;nbsp;therapy.... Patients with other primary tumor except lung &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...Age:18 to 80 Karnofsky performance status&amp;gt; 60 Diagnosis of lung &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor,nodes</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Relapse/Recurrence - Assessment of freedom from regional or distant recurrence</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HepaSphere Interventional Therapy Using Digital Subtraction Angiography (DSA) for Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Early Stage Lung Cancer - Subjects with stage II lung cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen</Name><Name>Lizhi Niu, PhD</Name></ContactNames></Trial><Trial Id="231457"><Indications><Indication>Pancreas tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02449967</Identifier><Identifier>PANCREATIC CANCER HEPASPHERE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Digital subtraction angiography alone</Intervention><Intervention>HepaSphere alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>DSA) for pancreatic &lt;b&gt;cancer&lt;/b&gt; compared to the pancreatic &lt;b&gt;cancer&lt;/b&gt; patients who did not receive any interventional therapy (control).... Patients with other primary tumor except pancreatic &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 80 years Karnofsky performance status&amp;gt; 60 Diagnosis of pancreatic &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HepaSphere Interventional Therapy Using Digital Subtraction Angiography (DSA) for Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer - TNM Stage II pancreatic cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer - TNM Stage III pancreatic cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Liu, PhD</Name></ContactNames></Trial><Trial Id="227078"><Indications><Indication>Metastatic pancreas cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2015-04-22T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02406846</Identifier><Identifier>PANCREATIC CANCER CTC 001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Flow cytometry alone</Intervention><Intervention>Reverse transcriptase polymerase chain reaction alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>acid (EDTA) - blood was drawn by vein puncture from patients with pancreatic &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers will be used to evaluate... Patients with other primary tumor except pancreatic &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 75 years Karnofsky performance status&amp;gt; 60 Diagnosis of pancreatic &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><BiomarkerNames><BiomarkerName>Circulating Tumor Cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chen Jibing, PhD</Name><Name>Li Yuan, Master</Name><Name>Zeng JianYing, Master</Name></ContactNames></Trial><Trial Id="35785"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytosine DNA methyltransferase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cancer Research UK</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2010-11-01T00:00:00Z</DateEnd><DateStart>2007-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000613805</Identifier><Identifier>CRUK-PH2/051</Identifier><Identifier>CTA-21106/0219/001</Identifier><Identifier>Decitabine and Carboplatin in Relapsed Ovarian Cancer</Identifier><Identifier>EUDRACT-2006-002324-41</Identifier><Identifier>MGI-CRUK-PH2/051</Identifier><Identifier>NCT00514124</Identifier><Identifier>NCT00748527</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>carboplatin alone</Intervention><Intervention>Variable regimens including carboplatin , carboplatin + decitabine , decitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>134</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Safety Issues</Reason></ReasonForTrialDiscontinuation><Teaser>epithelial &lt;b&gt;cancer&lt;/b&gt;, fallopian tube &lt;b&gt;cancer&lt;/b&gt;, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; who have methylated hMLH1 DNA in plasma treated with carboplatin...epithelial &lt;b&gt;cancer&lt;/b&gt;, fallopian tube &lt;b&gt;cancer&lt;/b&gt;, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; Progressive disease as defined by RECIST criteria and/or...weeks since prior major thoracic and/or abdominal surgery and recovered No other concurrent anti-&lt;b&gt;cancer&lt;/b&gt; therapy, including radiotherapy or investigational drugs</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of genetic marker</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Decitabine and Carboplatin in Relapsed Ovarian Cancer: Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Ovarian Cancer Subjects with CA-125 Expression</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Sensitive Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA-125 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Stanley B. Kaye, MD, FRCP</Name><Name>Stanley Kaye</Name></ContactNames></Trial><Trial Id="238254"><Indications><Indication>Endometrioid carcinoma</Indication><Indication>Metastatic ovary cancer</Indication><Indication>Ovarian clear cell carcinoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon beta ligand modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intraperitoneal formulation</Technology><Technology>Mesenchymal stem cell therapy</Technology></Technologies><CompaniesSponsor><Company>MD Anderson Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-05-31T00:00:00Z</DateEnd><DateStart>2016-05-16T00:00:00Z</DateStart><Identifiers><Identifier>2013-0032</Identifier><Identifier>CA 136411</Identifier><Identifier>NCI-2015-01504</Identifier><Identifier>NCT02530047</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mesenchymal stem cell therapy (ovarian cancer), MD Anderson Cancer Center alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Up to four dose levels of mesenchymal stem cell therapy (ovarian &lt;b&gt;cancer&lt;/b&gt;), MD Anderson &lt;b&gt;Cancer&lt;/b&gt; Center would be tested. Up to...Anderson &lt;b&gt;Cancer&lt;/b&gt; Center infusions. Mesenchymal stem cell therapy (ovarian &lt;b&gt;cancer&lt;/b&gt;), MD Anderson &lt;b&gt;Cancer&lt;/b&gt; Center would be administered on an outpatient basis...ovarian &lt;b&gt;cancer&lt;/b&gt;), MD Anderson &lt;b&gt;Cancer&lt;/b&gt; Center infusion, patients would have an intraperitoneal (IP) catheter placed in their abdomen. A catheter was a</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Liver function tests</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Organ Function - Assessment of hepatic function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Mesenchymal Stem Cells (MSC) for Ovarian Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with clear cell adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with endometrioid adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with mixed epithelial carcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with mucinous adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with undifferentiated carcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with H/O Solid Tumours Indicated for SCT</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Mesenchymal Stem Cell Transplantation(MSCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Actin, aortic smooth muscle </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Interferon beta </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amanda L. Olson</Name></ContactNames></Trial><Trial Id="288170"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Tubulin receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Immunotoxin</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody drug conjugate</Technology><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody conjugated</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>RemeGen Ltd</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-07-04T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2016-11-30T00:00:00Z</DateStart><Identifiers><Identifier>003 CANCER</Identifier><Identifier>C003 CANCER</Identifier><Identifier>NCT03052634</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Fatigue</Indication><Indication>Leukopenia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>capecitabine plus lapatinib</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>RC-48 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>165</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>within 2 weeks before study drug treatment Unresolved toxicities from prior anti-&lt;b&gt;cancer&lt;/b&gt; therapy, defined as having not resolved to Common Terminology Criteria for Adverse...advanced or metastatic advanced breast &lt;b&gt;cancer&lt;/b&gt; diagnosed by pathology and refractory to standard of care therapy, or for whom no standard of care therapy is available...ADC ) administered intravenously to subjects with HER2-positive in advanced breast &lt;b&gt;cancer&lt;/b&gt;. The primary objectives were to evaluate preliminary efficacy per RECIST</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lin Li</Name></ContactNames></Trial><Trial Id="307758"><Indications><Indication>Breast tumor</Indication><Indication>Metastatic breast cancer</Indication></Indications><CompaniesCollaborator><Company>Shengxin Biotechnology Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-01-28T00:00:00Z</DateChangeLast><DateEnd>2018-09-02T00:00:00Z</DateEnd><DateStart>2017-09-02T00:00:00Z</DateStart><Identifiers><Identifier>BIOINFORMATION-BREAST</Identifier><Identifier>NCT03240224</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cancer ablation alone</Intervention><Intervention>life information rehabilitation therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Qilisheng alone</Intervention><Intervention>cancer ablation alone</Intervention><Intervention>life information rehabilitation therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>breast &lt;b&gt;cancer&lt;/b&gt; adapted to enrolled criteria, this study would document for the first time the synergistic effect of &lt;b&gt;cancer&lt;/b&gt; ablation and life information rehabilitation therapy. The efficacy would be evaluated according to local relief... The aim of this study was to evaluate the synergistic effect of &lt;b&gt;cancer&lt;/b&gt; ablation and life information rehabilitation therapy on unresectable breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Breast tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Bioinformation Therapy for Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-09-02T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="35321"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2004-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000424461</Identifier><Identifier>LUD 2002-012</Identifier><Identifier>LUDWIG-LUD2002-012</Identifier><Identifier>NCT00112957</Identifier><Identifier>RPCI-I-13303</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rV-NY-ESO-1/rF-NY-ESO-1 prime-boost breast cancer vaccine, Ludwig Institute/Therion alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>23</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; Stage II to IV disease at diagnosis Tumor expression of one of the following: NY-ESO-1 by reverse transcription polymerase chain reaction (RT-PCR) analysis...peritoneal &lt;b&gt;cancer&lt;/b&gt;. The primary objective was to determine the remission rate in patients with NY-ESO-1 or LAGE-1 expressing stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; who are still in complete clinical</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Sensitive Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Fallopian Tube Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Peritoneal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cancer/testis antigen 2 </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kunle Odunsi, MD, PhD</Name></ContactNames></Trial><Trial Id="227851"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><CompaniesCollaborator><Company>Jinan University (Guangdong)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-29T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2015-04-30T00:00:00Z</DateStart><Identifiers><Identifier>GD T CELL AND LUNG CANCER</Identifier><Identifier>NCT02425748</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>DC-CIK cells alone</Intervention><Intervention>gamma delta T cells alone</Intervention><Intervention>DC-CIK cells plus gamma delta T Cell</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>would be separated from peripheral blood. After making them potential &lt;b&gt;cancer&lt;/b&gt; killer gamma delta T Cell and DC-CIK, they would be infused to the patients as immunotherapy.... Patients with other kinds of &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia Patients with heart disease and diabetes...to determine the effects of gamma delta T cells on human non small lung &lt;b&gt;cancer&lt;/b&gt; (without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Tumor Related Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>GD T CELL AND LUNG CANCER: Safety and Efficiency of Gamma Delta T Cell Against Non Small Lung Cancer (Without EGFR Mutation)</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="239179"><Indications><Indication>Breast tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>Breast Cancer HepaSphere</Identifier><Identifier>NCT02523417</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HepaSphere alone</Intervention><Intervention>digital subtraction angiography (DSA) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with other primary tumor except breast&amp;nbsp;&lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...to 80 years Karnofsky performance status &amp;gt; 60 Diagnosis of breast&amp;nbsp;&lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor...was to evaluate the safety and short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography (DSA) for breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HepaSphere Interventional Therapy Using Digital Subtraction Angiography (DSA) for Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen</Name><Name>Lizhi Niu, PhD</Name></ContactNames></Trial><Trial Id="231246"><Indications><Indication>Liver tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-26T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>LIVER CANCER HEPASPHERE</Identifier><Identifier>NCT02447263</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>digital subtraction angiography alone</Intervention><Intervention>hepasphere interventional therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>87</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>liver &lt;b&gt;cancer&lt;/b&gt;. Liver &lt;b&gt;cancer&lt;/b&gt; patients would receive (experimental) or would not receive (no intervention [control]) HepaSphere interventional therapy using the digital... Patients with other primary tumor except pancreatic &lt;b&gt;cancer&lt;/b&gt; History of coagulation...Age: 18 to 80 Karnofsky performance status&amp;gt; 60 Diagnosis of pancreatic &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HepaSphere Interventional Therapy Using Digital Subtraction Angiography (DSA) for Liver Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatobiliary system tumor - Subjects with specific disease - Subjects with hepatocellular carcinoma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Liu, PhD</Name></ContactNames></Trial><Trial Id="85063"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF-1 agonist</Action><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>GM-CSF receptor agonist</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiparkinsonian</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Hematopoietic stimulator</Action><Action>Immunostimulant</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-27T00:00:00Z</DateChangeLast><DateEnd>2019-06-01T00:00:00Z</DateEnd><DateStart>2012-08-20T00:00:00Z</DateStart><Identifiers><Identifier>I 199911</Identifier><Identifier>NCI-2011-02964</Identifier><Identifier>NCT01536054</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including autologous NY-ESO-1-targeting dendritic cell vaccine (cancer), Roswell Park Comprehensive Cancer Center , sargramostim , sirolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>7</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>asymptomatic residual measurable disease on physical examination and/or (computed tomography) CT scan, and/or may have an elevated &lt;b&gt;cancer&lt;/b&gt; antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these...1 (M)/TRICOM vaccine in treating patients with stage II to IV ovarian epithelial, fallopian tube, or primary peritoneal cavity &lt;b&gt;cancer&lt;/b&gt;. The primary objective of this study is to determine the safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine with</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of antitumor activity</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Sirolimus and Vaccine Therapy in Treating Patients With Stage II to IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cancer/testis antigen 1 </BiomarkerName><BiomarkerName> Cancer/testis antigen 2 </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Forkhead box protein P3 </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Memory T-Lymphocytes </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-04-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>81 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kunle Odunsi</Name><Name>Roswell¬†Park</Name></ContactNames></Trial><Trial Id="205030"><Indications><Indication>Metastatic ovary cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Dendritic cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Stem cell therapy</Technology></Technologies><CompaniesCollaborator><Company>University of Michigan</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2017-07-19T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2014-06-30T00:00:00Z</DateStart><Identifiers><Identifier>201401</Identifier><Identifier>CLO-001</Identifier><Identifier>NCT02178670</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>CSC-enriched tumor lysate-pulsed dendritic cell vaccine (cancer), University of Michigan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>vaccine ( CSC-DC ). Arm4: patients would receive high dose vaccine ( CSC-DC ). The using dosage,frequency and duration of &lt;b&gt;cancer&lt;/b&gt; stem cell vaccine would be still undetermined....skin &lt;b&gt;cancer&lt;/b&gt; or cervical &lt;b&gt;cancer&lt;/b&gt; in situ Presence of an active acute or chronic infection, including syphilis...confirmed FIGO stage III ovarian epithelial &lt;b&gt;cancer&lt;/b&gt; Stable disease at screening visit: negative CT and CA-125 within normal range Karnofsky</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs)</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with unspecified adenocarcinomas of the ovaries</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA-125 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="168965"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2017-08-31T00:00:00Z</DateEnd><DateStart>2011-03-25T00:00:00Z</DateStart><Identifiers><Identifier>8821</Identifier><Identifier>CDR0000696902</Identifier><Identifier>MAYO-MC093C</Identifier><Identifier>MC093C</Identifier><Identifier>NCI-2011-00847</Identifier><Identifier>NCT01327781</Identifier><Identifier>P30CA015083</Identifier><Identifier>P50CA116201</Identifier><Identifier>U01CA069912</Identifier><Identifier>UM1CA186686</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Anxiety disorder</Indication><Indication>Chronic fatigue syndrome</Indication><Indication>Edema</Indication><Indication>Fatigue</Indication><Indication>Hot flashes</Indication><Indication>Hypersomnia</Indication><Indication>Hypertriglyceridemia</Indication><Indication>Hypoalbuminemia</Indication><Indication>Hypophosphatemia</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Paresthesia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Seizure disorder</Indication><Indication>Thromboembolism</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Z-endoxifen hydrochloride (metastatic breast cancer), National Cancer Institute/Mayo Clinic Arizon/Mayo Clinic Minnesota alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>recurred&amp;lt; 2 years prior to registration; exceptions: non-melanotic skin &lt;b&gt;cancer&lt;/b&gt; or carcinoma-in-situ of the cervix Any co-morbid systemic illnesses or other severe... Histologically confirmed diagnosis of metastatic or locally recurrent breast &lt;b&gt;cancer&lt;/b&gt; ER positive defined as&amp;gt; 1% nuclear staining on the biopsy that was obtained...of Z-endoxifen hydrochloride or the dose level associated with endoxifen steady state concentration (Css) of at least 2 microM in women with metastatic estrogen-receptor positive (ER+) breast &lt;b&gt;cancer&lt;/b&gt; (dose-escalation cohort</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Bone/Cartilage/Collagen Turnover</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Hormone Receptor Status - Estrogen receptor status</EndpointIndex><EndpointIndex>Breast tumor - Hormone Receptor Status - Progesterone receptor status</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Hot flashes</EndpointIndex><EndpointIndex>Menopause - Assessment of Biomarkers - Assessment of bone markers</EndpointIndex><EndpointIndex>Menopause - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Menopause - Assessment of Therapy Related Outcomes - Assessment of response to cancer therapy</EndpointIndex><EndpointIndex>Menopause - Patient Reported Outcomes/Quality of Life Assessments - Assessment of hot flashes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-positive Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment><PatientSegment>Menopause - Subjects with Vasomotor Symptoms</PatientSegment><PatientSegment>Menopause - Subjects with comorbid conditions - Subjects with Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Cellular tumor antigen p53 </BiomarkerName><BiomarkerName> ERK1/2 </BiomarkerName><BiomarkerName> Epidermal growth factor receptor </BiomarkerName><BiomarkerName> Estrogen receptor </BiomarkerName><BiomarkerName> FKBP12-rapamycin complex-associated protein </BiomarkerName><BiomarkerName> G1/S-specific cyclin-D1 </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 receptor </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Nuclear receptor coactivator 1 </BiomarkerName><BiomarkerName> Nuclear receptor coactivator 3 </BiomarkerName><BiomarkerName> Phosphatidylinositol 3-Kinase </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </BiomarkerName><BiomarkerName> RAC-alpha serine/threonine-protein kinase </BiomarkerName><BiomarkerName> Ribosomal protein S6 kinases </BiomarkerName><BiomarkerName> Total cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-03-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Matthew P Goetz</Name></ContactNames></Trial><Trial Id="210929"><Indications><Indication>Cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AMP activated protein kinase stimulator</Action><Action>HMG CoA reductase inhibitor</Action><Action>Tubulin binding agent</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Antiarteriosclerotic</Action><Action>Antibacterial</Action><Action>Anticancer</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antiparasitic</Action><Action>Apoptosis stimulator</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Biguanide antidiabetic product</Action><Action>Cell cycle inhibitor</Action><Action>Hypoglycemic agent</Action><Action>Microtubule inhibitor</Action><Action>Ribosome binding agent</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Health Clinics Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2023-10-22T00:00:00Z</DateEnd><DateStart>2017-05-22T00:00:00Z</DateStart><Identifiers><Identifier>METABOLIC CANCER 001</Identifier><Identifier>METRICS</Identifier><Identifier>NCT02201381</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atorvastatin , doxycycline hyclate , mebendazole (cancer), Introgen Therapeutics , metformin hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>207</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>or European Organization for Research and Treatment of &lt;b&gt;Cancer&lt;/b&gt; Quality of Life Questionnaire [EORTC-QLQ]). All patients would be on the same drug regimen...progression-free survival (PFS) associated with the study regimen for each type of &lt;b&gt;cancer&lt;/b&gt;. Estimates of PFS would be presented for various time points with associated confidence...each &lt;b&gt;cancer&lt;/b&gt; type with confidence intervals. The relationship between changes in biochemistry values (glucose, lipids) and efficacy outcomes (PFS, overall survival [OS</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Historical Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>METRICS: Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer</TitleDisplay><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> LDL-C/HDL-C ratio </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-05-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christina Doherty</Name><Name>Gregory Stoloff</Name><Name>Robin Bannister, PhD</Name><Name>Samir Agrawal, MRCP FRCPath</Name></ContactNames></Trial><Trial Id="142255"><Indications><Indication>Hormone dependent prostate cancer</Indication><Indication>Metastatic prostate cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glutamate carboxypeptidase II modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>T-lymphocyte</Technology></Technologies><CompaniesCollaborator><Company>US Department of Defense</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2010-06-30T00:00:00Z</DateStart><Identifiers><Identifier>09-036</Identifier><Identifier>NCT01140373</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>anti-PSMA CAR T-cell therapy (prostate cancer), Memorial Sloan-Kettering Cancer Center alone</Intervention><Intervention>cyclophosphamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>a gene so that they might be able to better recognize and kill the prostate &lt;b&gt;cancer&lt;/b&gt; cells. The gene would be put into the patients T-cells by a weakened virus. There...malignant &lt;b&gt;cancer&lt;/b&gt;, except for non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; within previous five years History of splenectomy Autoimmune- or Ab-mediated disease including, but not...erythropoietin Medroxyprogesterone as an appetite stimulant Alternative medicine treatments for prostate &lt;b&gt;cancer&lt;/b&gt;, including Prostasol (formerly: PC-Plus), saw palmetto, or Zyflamend</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of metastasis</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Metastasis - Assessment of bone metastasis</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 3 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 4 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Adoptive Transfer of Autologs T-Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Castrate Resistant Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Prostate-specific antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>108 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Howard Scher</Name><Name>Howard Scher, MD</Name><Name>Susan Slovin</Name><Name>Susan Slovin, MD, PhD</Name><Name>Susan Slovin, MD. PhD</Name></ContactNames></Trial><Trial Id="60138"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>GM-CSF receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>GM-CSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Recombinant vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Recombinant vector vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sidney Kimmel Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-13T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000653173</Identifier><Identifier>GENENTECH-JHOC-J0947</Identifier><Identifier>J0947</Identifier><Identifier>J0947 CDR0000653173</Identifier><Identifier>JHOC-J0947</Identifier><Identifier>NA_00024527</Identifier><Identifier>NCT00971737</Identifier><Identifier>P30CA006973</Identifier></Identifiers><InterventionsControlDisplay><Intervention>GM-CSF cancer vaccine, Thomas Jefferson/NCI plus cyclophosphamide</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including GM-CSF cancer vaccine, Thomas Jefferson/NCI , cyclophosphamide , trastuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>63</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would receive cyclophosphamide and GM-CSF &lt;b&gt;cancer&lt;/b&gt; vaccine as in arm I and trastuzumab iv over 30 to 90 min on day -1. Courses repeat every ...be eligible for therapy of known curative potential for metastatic breast &lt;b&gt;cancer&lt;/b&gt; Measurable or evaluable disease Stable CNS disease allowed provided that it's...skin &lt;b&gt;cancer&lt;/b&gt;, superficial bladder &lt;b&gt;cancer&lt;/b&gt;, or tamoxifen-related endometrial &lt;b&gt;cancer&lt;/b&gt; that has</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of inflammatory/proinflammatory cytokine levels</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Lysosome-associated membrane glycoprotein 1 </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>80 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Leisha A. Emens, MD, PhD</Name></ContactNames></Trial><Trial Id="35315"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>Interferon agonist</Action><Action>TLR-3 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Corticosteroid agonist</Action><Action>IL release stimulator</Action><Action>Immunostimulant</Action><Action>Natural killer cell stimulator</Action><Action>Protein subunit vaccine</Action><Action>T-lymphocyte stimulator</Action><Action>TNF release modulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Suspension</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>LUD2006-001</Identifier><Identifier>MSKCC IRB# 07-152</Identifier><Identifier>NCT00616941</Identifier></Identifiers><IndicationsAdverse><Indication>Fatigue</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>NY-ESO-1 vaccine (peptides), Ludwig Institute/Peking University/Jewim Pharmaceutical alone</Intervention><Intervention>Variable regimens including Montanide ISA-51 , NY-ESO-1 vaccine (peptides), Ludwig Institute/Peking University/Jewim Pharmaceutical , Poly-ICLC</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>28</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>years prior to entry into the study, except for treated non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; and cervical carcinoma in situ History of previous severe allergic reactions to vaccines...platinum-based chemotherapy regimen In second or third stable complete clinical remission, defined as: Stable &lt;b&gt;cancer&lt;/b&gt; antigen (CA)-125&amp;lt; 35 U/ml (defined as CA-125 that had...Poly-ICLC in patients with epithelial ovarian, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; in second or third clinical remission. The objective of the study was</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase I Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA-125 antigen </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Paul Sabbatini, MD</Name></ContactNames></Trial><Trial Id="137573"><Indications><Indication>Metastatic rectal cancer</Indication></Indications><CompaniesCollaborator><Company>Australian Government</Company><Company>National Health and Medical Research Council</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-02-13T00:00:00Z</DateChangeLast><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>362246</Identifier><Identifier>ACTRN12612000327886</Identifier><Identifier>UTN: U1111-1129-1350</Identifier><Identifier>ctDNA Rectal cancer</Identifier></Identifiers><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>primary &lt;b&gt;cancer&lt;/b&gt; within the last five years, with the exception of nonmelanomatous skin &lt;b&gt;cancer&lt;/b&gt; and carcinoma in situ of the cervix Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol Patients...rectal &lt;b&gt;cancer&lt;/b&gt;. This was an exploratory, prospective study involving the collection of blood samples for the purposes of measuring ctDNA from patients with locally advanced rectal &lt;b&gt;cancer&lt;/b&gt; planned for pre-operative</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ctDNA Rectal cancer: Circulating Tumor DNA as a Marker of Complete Pathological Response and Long Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative Chemoradiotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jeanne Tie</Name><Name>Philippa Robertson</Name></ContactNames></Trial><Trial Id="263136"><Indications><Indication>Ataxia telangiectasia</Indication><Indication>Breast tumor</Indication><Indication>Colorectal tumor</Indication><Indication>Familial adenomatous polyposis</Indication><Indication>Li Fraumeni syndrome</Indication><Indication>Melanoma</Indication><Indication>Multiple hamartoma sydrome</Indication><Indication>Ovary tumor</Indication><Indication>Pancreatitis</Indication><Indication>Peutz Jegher syndrome</Indication><Indication>Stomach tumor</Indication></Indications><CompaniesCollaborator><Company>Stanford University</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Southern California</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-10-13T00:00:00Z</DateChangeLast><DateEnd>2017-01-05T00:00:00Z</DateEnd><DateStart>2014-06-12T00:00:00Z</DateStart><Identifiers><Identifier>0S-13-1</Identifier><Identifier>HCP</Identifier><Identifier>NCT02324062</Identifier><Identifier>Study 005</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>myRisk Hereditary Cancer test alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2000</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>presented. A 11.6% of subjects had a deleterious mutation in a &lt;b&gt;cancer&lt;/b&gt; susceptibility gene.&amp;nbsp;Self-reported preventative&amp;nbsp;surgery rates were low (mastectomy 9.2%, hysterectomy...a VUS or negative result was observed.&amp;nbsp;Most subjects never had thoughts of &lt;b&gt;cancer&lt;/b&gt; affecting their daily activities, did not regret testing and wanted to know the...pre-clinic questionnaire would be sent to the subjects prior to their assessment in &lt;b&gt;cancer&lt;/b&gt; genetics clinic in order to obtain baseline information that would be used to</Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of markers of cancer risk/recurrence risk</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of genetic tests - unspecified</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of mutation of genes</EndpointIndex><EndpointIndex>Breast tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - CRC Risk Factor Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Laboratory Assessment</EndpointIndex><EndpointIndex>Melanoma - Assessment of Biomarkers - Assessment of genetic markers</EndpointIndex><EndpointIndex>Melanoma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Melanoma - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Melanoma - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Melanoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Melanoma - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Clinical Symptoms - Assessment of neurological/psychological symptoms</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Ovary tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of genetic marker</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Neuropsychological Function - Neuropsychological assessment</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Solid tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Risk Factors</EndpointIndex><EndpointIndex>Stomach tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Stomach tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Stomach tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>HCP: Cancer Genetics Hereditary Cancer Panel Testing</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects at Risk of Developing Invasive Breast Cancer</PatientSegment><PatientSegment>Colorectal tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Colorectal tumor - Subjects at risk of developing disease</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Melanoma - Others - Healthy Subjects</PatientSegment><PatientSegment>Melanoma - Subjects at risk of developing disease</PatientSegment><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease</PatientSegment><PatientSegment>Ovary tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects at risk of developing disease</PatientSegment><PatientSegment>Solid tumor - Others - Healthy Subjects</PatientSegment><PatientSegment>Stomach tumor - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>A/G-specific adenine DNA glycosylase </BiomarkerName><BiomarkerName> Adenomatous polyposis coli protein </BiomarkerName><BiomarkerName> Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein </BiomarkerName><BiomarkerName> DNA mismatch repair protein MSH6 </BiomarkerName><BiomarkerName> DNA mismatch repair protein Mlh1 </BiomarkerName><BiomarkerName> DNA mismatch repair protein Msh2 </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> Serine-protein kinase ATM </BiomarkerName><BiomarkerName> Serine/threonine-protein kinase Chk2 </BiomarkerName><BiomarkerName> myRisk panel</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-01-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Gregory Idos, MD</Name></ContactNames></Trial><Trial Id="80938"><Indications><Indication>Adenocarcinoma</Indication><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>BIK gene modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Unspecified non-viral vector based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Liposome formulation injectable</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>MD Anderson Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>1 R21 CA135 60401A1</Identifier><Identifier>2007-0762</Identifier><Identifier>NCI-2011-00466</Identifier><Identifier>NCT00968604</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BikDD gene therapy (VISA, cancer), MD Anderson Cancer Center alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>would be able to reach the tumor and what effect it would have on the &lt;b&gt;cancer&lt;/b&gt;. Patients would stay awake during the biopsy. A radiologist would find the tumor with...to learn if VISA BikDD nanoparticle was reaching the tumor and its effect on &lt;b&gt;cancer&lt;/b&gt;. If for any reason the biopsy couldn't be performed then, patients might be...CT scan or MRI of the chest, abdomen, and pelvis 4 to 6 weeks later. If the &lt;b&gt;cancer&lt;/b&gt; was worse, patients would stop BikDD . On day 1 of cycles 3 and beyond, the following</Teaser><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>C-VISA BikDD: liposome in Advanced Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Adenocarcinoma of Pancreas</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Unresectable Pancreatic Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA19-9 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-03-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Milind Javle, MD</Name></ContactNames></Trial><Trial Id="231405"><Indications><Indication>Metastatic liver cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2017-07-21T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02449109</Identifier><Identifier>Nano drug liver cancer</Identifier></Identifiers><InterventionsControlDisplay><Intervention>HepaSphere alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>digital subtraction angiography alone</Intervention><Intervention>gemcitabine plus glycyrrhizin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with other primary tumor except liver &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...Age:18 to 80 Karnofsky performance status &amp;gt; 60 Diagnosis of liver &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures. Classification tumor, nodes...efficacy of nano drug ( Gemzar mix with compound glycyrrhizin injection) interventional therapy using digital subtraction angiography (DSA) for liver &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Nano Drug Interventional Therapy Using Digital Subtraction Angiography (DSA) for Liver Carcinoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Locally Advanced Primary Liver Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chen Jibing</Name><Name>Lizhi Niu, PhD</Name><Name>Xianghao Piao, PhD</Name><Name>Yuan Li, Master</Name></ContactNames></Trial><Trial Id="258152"><Indications><Indication>Hormone refractory prostate cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Cytochrome P450 17 inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 17 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Nanoparticle formulation oral</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Churchill Pharmaceuticals LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-04-18T00:00:00Z</DateChangeLast><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>CHL-AA-201</Identifier><Identifier>NCT02737332</Identifier><Identifier>STAAR</Identifier></Identifiers><IndicationsAdverse><Indication>Death</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>abiraterone acetate (oral nanoparticle formulation/SoluMatrix, prostate cancer), iCeutica/Sun Pharmaceutical alone</Intervention><Intervention>abiraterone acetate (oral nanoparticle formulation/SoluMatrix, prostate cancer), iCeutica/Sun Pharmaceutical plus prednisone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>abiraterone acetate (oral nanoparticle formulation/SoluMatrix, prostate cancer), iCeutica/Sun Pharmaceutical alone</Intervention><Intervention>abiraterone acetate (oral nanoparticle formulation/SoluMatrix, prostate cancer), iCeutica/Sun Pharmaceutical plus methylprednisolone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> At least 50 patients with metastatic castration-resistant prostate &lt;b&gt;cancer&lt;/b&gt; would be enrolled in this trial. Patients would receive Zytiga 1000 mg (4 x 250 mg...will be accepted Meeting disease progression according to the recommendations of the prostate &lt;b&gt;cancer&lt;/b&gt; working group 2 by one of the following criteria: Two rises of...pharmacokinetics of YONSA, in men with progressive metastatic castration-resistant prostate &lt;b&gt;cancer&lt;/b&gt;. Of 14 patients, the pharmacokinetic samples were evaluated for 5</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Hormone Levels - Assessment of testosterone levels</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of treatment emergent adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STAAR: A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Castrate Resistant Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with Rising PSA levels</PatientSegment><PatientSegment>Prostate tumor - Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Prostate-specific antigen </BiomarkerName><BiomarkerName> Testosterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2016-12-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>17</NumberOfSites><ContactNames><Name>Amy Boucher</Name><Name>Charity Hernandez, LVN</Name><Name>Diane Tichota</Name><Name>Jacqueline Huskins</Name><Name>Jennifer Kucenski, CCRC</Name><Name>Kris Wheeler, RN, CCRC</Name><Name>Kristen Bettino, CCRP</Name><Name>Laura Weber</Name><Name>Lenden Neeper, MS, CCRP</Name><Name>Patti Patterson, RN</Name><Name>Paul Nemeth, Ph.D.</Name><Name>Yvonne Rivas</Name></ContactNames></Trial><Trial Id="367954"><Indications><Indication>Solid tumor</Indication></Indications><CompaniesCollaborator><Company>Shanghai Asclepius Meditec Co., Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital-Guangzhou</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-01-30T00:00:00Z</DateChangeLast><DateEnd>2022-02-12T00:00:00Z</DateEnd><DateStart>2019-02-12T00:00:00Z</DateStart><Identifiers><Identifier>HYDROGEN-CANCER</Identifier><Identifier>NCT03818347</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hydrogen gas immunotherapy alone</Intervention><Intervention>oxyhydrogen generator (BYT-CH-H01) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>By enrolling patients of multiple kinds of &lt;b&gt;cancer&lt;/b&gt; adapted to enrolled criteria, this study will document for the first time the short and long term efficacy of hydrogen gas.The evaluation indexes will include peripheral blood lymphocyte immunoassay... The aim of this study is to check the efficacy of hydrogen gas immunotherapy to rehabilitation and prognosis of &lt;b&gt;cancer&lt;/b&gt; patients.</Teaser><TrialCategories><Category>Medical device</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Solid tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Sleep</EndpointIndex><EndpointIndex>Solid tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints - Assessment of hematological status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Hydrogen Gas for Cancer Rehabilitation</TitleDisplay><BiomarkerNames><BiomarkerName>Alpha-fetoprotein </BiomarkerName><BiomarkerName> Circulating Tumor Cells </BiomarkerName><BiomarkerName> Natural killer cells </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-02-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rita Lu, MD</Name></ContactNames></Trial><Trial Id="88528"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Metastatic breast cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PARP inhibitor</Action><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>Phosphoinositide-3 kinase alpha inhibitor</Action><Action>Poly ADP ribose polymerase 1 inhibitor</Action><Action>Poly ADP ribose polymerase 2 inhibitor</Action><Action>Poly ADP ribose polymerase 3 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Metastasis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>AstraZeneca plc</Company><Company>Breast Cancer Research Foundation of Alabama</Company><Company>National Ovarian Cancer Coalition</Company><Company>Novartis AG</Company><Company>Stand Up To Cancer</Company><Company>The Ovarian Cancer Research Fund</Company></CompaniesCollaborator><CompaniesSponsor><Company>Dana-Farber Cancer Institute Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-18T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>12-159</Identifier><Identifier>NCT01623349</Identifier></Identifiers><IndicationsAdverse><Indication>Depression</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Hyperglycemia</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including alpelisib , buparlisib , olaparib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>and additionally included grade 3 depression and transaminitis in early cycle 2 (DL7). In breast &lt;b&gt;cancer&lt;/b&gt; and ovarain &lt;b&gt;cancer&lt;/b&gt; and also in gBRCAm and gBRCA wild type patients, anticancer activity...ovarian &lt;b&gt;cancer&lt;/b&gt; and in patients with breast &lt;b&gt;cancer&lt;/b&gt;, who received at least one dose of the study drugs. Considering all dose levels...patients &lt;b&gt;cancer&lt;/b&gt; to see if researchers can learn more about patients type of &lt;b&gt;cancer&lt;/b&gt; and understand how this combination of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Breast tumor - Protocol Specified Other Endpoints - Assessment of Antitumor Activity</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of BRCA1/BRCA2</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase I Study of the Oral PI3kinase Inhibitor BKM-120 or BYL-719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with Triple Negative Breast Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with Grade-3 or High Grade Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with serous adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>63 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Alan D-Andrea</Name><Name>Blair Station</Name><Name>Brian Lasonde</Name><Name>Christin Whalen, RN</Name><Name>Gerburg Wulf, MD</Name><Name>Katherine Bell-McGuinn, MD</Name><Name>Katherine Bell-mcguinn</Name><Name>Kathryn Componeschi</Name><Name>Meghan Comeau</Name><Name>Michael Birrer</Name><Name>Michael Birrer, MD, PhD</Name><Name>Michael Garcia</Name><Name>Robert Shaw</Name><Name>Sara Kravetz</Name><Name>Sarah Farooq</Name><Name>Susan McIntyre</Name><Name>Tina Atkinson</Name><Name>Ursula A. Matulonis, M.D.</Name><Name>Ursula Matulonis</Name><Name>Ursula Matulonis, MD</Name></ContactNames></Trial><Trial Id="311844"><Indications><Indication>Bladder cancer</Indication></Indications><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2017-10-31T00:00:00Z</DateStart><Identifiers><Identifier>Bl Cancer</Identifier><Identifier>NCT03274284</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chemotherapy alone</Intervention><Intervention>cisplatin alone</Intervention><Intervention>radiotherapy (55, 64 Gy) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> All patients with recurrent T1G3 bladder &lt;b&gt;cancer&lt;/b&gt; after six doses of BCG consenting for chemoradiation and refusing radical cystectomy... The aim of this study is to evaluate the short term results of chemoradiation in case of T1G3 Bladder &lt;b&gt;Cancer&lt;/b&gt; after Bacille Calmette Guerin (BCG) failure. The major goal of treatment for T1G3 BC should be bladder preservation whenever possible</Teaser><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Survival</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Chemoradiotherapy for Recurrent T1G3 Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease - Refractory to BCG therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Ahmed Moeen</Name><Name>Diaa El Din Mohamed</Name><Name>moktar dawood</Name></ContactNames></Trial><Trial Id="375550"><Indications><Indication>Cancer</Indication></Indications><CompaniesSponsor><Company>MD Global, Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-07T00:00:00Z</DateChangeLast><DateEnd>2024-08-01T00:00:00Z</DateEnd><DateStart>2019-03-26T00:00:00Z</DateStart><Identifiers><Identifier>02252019</Identifier><Identifier>NCT03897374</Identifier><Identifier>STOP-Cancer</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>genetic analysis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180000</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>will be limited to study subjects &amp;gt; 18 years who have received a hereditary &lt;b&gt;cancer&lt;/b&gt; genomic diagnostic test results no more than 90 days prior to consent. The genes...hereditary &lt;b&gt;cancer&lt;/b&gt; genomic test will be ordered by a physician related to individual study subject care considerations. The hereditary &lt;b&gt;cancer&lt;/b&gt; testing is independent...hereditary &lt;b&gt;cancer&lt;/b&gt; genomic testing serves as criteria for eligibility in the study and must have been ordered for medical necessity and results received</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Case Control</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Solid tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Solid tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STOP-Cancer: Strategic Targeting for Optimal Prevention of Cancer</TitleDisplay><BiomarkerNames><BiomarkerName>39S ribosomal protein L36, mitochondrial </BiomarkerName><BiomarkerName> BRCA1-associated RING domain protein 1 </BiomarkerName><BiomarkerName> Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein </BiomarkerName><BiomarkerName> Cellular tumor antigen p53 </BiomarkerName><BiomarkerName> DNA mismatch repair protein MSH6 </BiomarkerName><BiomarkerName> DNA mismatch repair protein Mlh1 </BiomarkerName><BiomarkerName> DNA mismatch repair protein Msh2 </BiomarkerName><BiomarkerName> DNA repair protein RAD50 </BiomarkerName><BiomarkerName> DNA repair protein RAD51 homolog 3 </BiomarkerName><BiomarkerName> DNA repair protein RAD51 homolog 4 </BiomarkerName><BiomarkerName> DNA-repair protein XRCC2 </BiomarkerName><BiomarkerName> Double-strand break repair protein MRE11A </BiomarkerName><BiomarkerName> Fizzy-related protein homolog </BiomarkerName><BiomarkerName> Mismatch repair endonuclease PMS2 </BiomarkerName><BiomarkerName> Nibrin </BiomarkerName><BiomarkerName> Partner and localizer of BRCA2 </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> RAD50-interacting protein 1 </BiomarkerName><BiomarkerName> Serine-protein kinase ATM </BiomarkerName><BiomarkerName> Serine/threonine-protein kinase Chk2 </BiomarkerName><BiomarkerName> Tumor-associated calcium signal transducer 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2024-04-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>64 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Diana Messir</Name><Name>Marvin Inscore</Name></ContactNames></Trial><Trial Id="158336"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AKT protein kinase inhibitor</Action><Action>MEK-1 protein kinase inhibitor</Action><Action>MEK-2 protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateStart>2013-10-02T00:00:00Z</DateStart><Identifiers><Identifier>2013C0069</Identifier><Identifier>9455</Identifier><Identifier>N01CM00070</Identifier><Identifier>N01CM00100</Identifier><Identifier>NCI 9455</Identifier><Identifier>NCI-2013-01895</Identifier><Identifier>NCI-2013-01895</Identifier><Identifier>NCT01964924</Identifier><Identifier>OSU 13117</Identifier><Identifier>P30CA016058</Identifier><Identifier>UM1CA186716</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>trametinib alone</Intervention><Intervention>trametinib plus uprosertib + trametinib (cancer), Laekna Therapeutics</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>years, or patients with a history of completely resected non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; and/or patients with indolent secondary malignancies, are eligible History of...medication; the following medications or non-drug therapies are prohibited: Other anti-&lt;b&gt;cancer&lt;/b&gt; therapy while on study treatment (megestrol if used as an appetite stimulant...least one and no &amp;gt; 3 prior chemotherapy regimens for the treatment of metastatic breast &lt;b&gt;cancer&lt;/b&gt; Patients must consent to both a pretreatment and</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT - Endocrine Symptoms (FACT-ES)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Trametinib and Akt Inhibitor GSK-2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Triple Negative Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estrogen receptor </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> Progesterone receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-06-01T00:00:00Z</PrimaryCompletionDate><NumberOfSites>8</NumberOfSites><ContactNames><Name>Andrew Poklepovic</Name><Name>Bhuvaneswari Ramaswamy</Name><Name>Claudine Isaacs</Name><Name>Ellis Levine</Name><Name>Erin Olson</Name><Name>George Budd</Name><Name>Julie Means-Powell</Name><Name>Lisa Carey</Name><Name>Lyndsay Harris</Name><Name>Susan Minton</Name></ContactNames></Trial><Trial Id="196929"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesCollaborator><Company>Brigham &amp; Women's Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Dana-Farber Cancer Institute Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-05T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2005-11-07T00:00:00Z</DateStart><Identifiers><Identifier>05-111</Identifier><Identifier>NCT00317603</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous lethally irradiated breast cancer cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>as adenoviral mediated gene transfer, which adds a new gene to the &lt;b&gt;cancer&lt;/b&gt; cells. The cells are then given radiation so that they will not grow. Patients will start receiving...vaccine depends upon the total amount of cells that are obtained from the breast &lt;b&gt;cancer&lt;/b&gt; tumor or fluid. Each time the patient is vaccinated, they will be given... Histologically confirmed stage IV breast &lt;b&gt;cancer&lt;/b&gt; Prior banked malignant effusion or significant malignant effusion for tumor harvest or surgically-accessible</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>163 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Beth Overmoyer, MD</Name><Name>Karen Anderson</Name></ContactNames></Trial><Trial Id="335187"><Indications><Indication>Metastatic liver cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2021-03-25T00:00:00Z</DateEnd><DateStart>2018-03-25T00:00:00Z</DateStart><Identifiers><Identifier>CIK AND BISPECIFIC ANTIBODY</Identifier><Identifier>NCT03484962</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cryotherapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>2 (experimental): patients will receive mixed liquor of activated CIK and anti-CD3/anti-MUC1 BiTE cytokine induced killer cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical together with cryotherapy (...second primary tumor or mutiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma„ÄÅmyeloma,and patients are using immunosuppressant Systemic autoimmune diseases, allergic constitution or immunocompromised patients Patients... Age 18 to 75 years old The patient is diagnosed as advanced liver &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured,and length &amp;gt;/= 10 mm</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatobiliary system tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA19-9 antigen </BiomarkerName><BiomarkerName> Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-25T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Chen Jibing, PhD</Name><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="245185"><Indications><Indication>Cancer</Indication></Indications><CompaniesCollaborator><Company>B√∏rnecancerfonden</Company><Company>Danish Cancer Society</Company><Company>Ronald McDonalds B√∏rnefond</Company><Company>Trygfonden</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aarhus University</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2016-05-13T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2014-08-31T00:00:00Z</DateStart><Identifiers><Identifier>MF-CANCER-CHILDREN-1</Identifier><Identifier>NCT02583139</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Designed Music Narratives alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>five (dependent on their overall plan of medical treatment) consecutive courses of chemotherapy administrated at the involved child &lt;b&gt;cancer&lt;/b&gt; units and (administered) over a period of minimum 24 h incl. hydration with assumed moderate to severe nausea... The purpose of this study is to determine whether a specially-designed music-narratives are effective in reducing side effects of chemotherapy in 7 to 12 year-olds with &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Cachexia/Weight Loss</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Fatigue</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting - Assessment by Visual Analogue Scale of nausea</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Condensed Memorial Symptom Assessment Scale (CMSAS)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7 to 12 Years) With Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting - Highly emetic chemotherapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Neutrophils </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>52 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Henrik Hasle, Prof. PhD MD</Name><Name>Ilan Sanfi, PhD</Name><Name>Lisbeth Rasmussen</Name><Name>Stine C. √Ür√∏, BA</Name></ContactNames></Trial><Trial Id="359350"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Metastatic ovary cancer</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intraperitoneal formulation</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-12T00:00:00Z</DateChangeLast><DateEnd>2021-05-03T00:00:00Z</DateEnd><DateStart>2019-04-15T00:00:00Z</DateStart><Identifiers><Identifier>I 60417</Identifier><Identifier>I 60417</Identifier><Identifier>NCI-2018-02337</Identifier><Identifier>NCT03735589</Identifier><Identifier>P30CA016056</Identifier><Identifier>P50CA159981</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous natural killer cell-like cytotoxic T-lymphocytes (intraperitoneal, ovarian cancer/peritoneal cancer/fallopian tube cancer), Roswell Park Cancer Institute/NCI alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>of other malignancy being present within the last three years. Patients are also excluded if their previous &lt;b&gt;cancer&lt;/b&gt; treatment contraindicates this protocol therapy...to IV ovarian, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt;. Primary objectives: To evaluate the safety, tolerability, and feasibility of intraperitoneal (i.p.) administration...progression-free survival and overall survival of patients treated with this combination. autologous NK cell-like cytotoxic T-lymphocytes (&lt;b&gt;cancer&lt;/b&gt;), Roswell Park/NCI</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of antitumor activity</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II to IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Fallopian Tube Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Peritoneal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> NKG2-D type II integral membrane protein </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-05-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kunle Odunsi</Name></ContactNames></Trial><Trial Id="167043"><Indications><Indication>Metastatic prostate cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Intratumoral formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Tumor antigen</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Jonsson Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-12T00:00:00Z</DateChangeLast><DateStart>2000-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000067981</Identifier><Identifier>NCI-G00-1802</Identifier><Identifier>NCT00005992</Identifier><Identifier>UCLA-9909056-02B</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>DCVax-Direct alone</Intervention><Intervention>PSA prostate cancer vaccine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Disease characteristics: Histologically confirmed metastatic hormone-refractory prostate &lt;b&gt;cancer&lt;/b&gt; Castrate serum testosterone&amp;lt; 30 ng/dl after antiandrogen withdrawal Progressing disease 50% increase in PSA level from the nadir PSA level confirmed...membrane antigen (rPSMA)-pulsed autologous dendritic cells ( CaPVax ) in patients with metastatic hormone-refractory prostate &lt;b&gt;cancer&lt;/b&gt;. Determine the potential clinical response in patients treated with this regimen. Determine the effect of this</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of pain</EndpointIndex><EndpointIndex>Prostate tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase I Clinical Trial of Recombinant Prostate Specific Membrane Antigen (rPSMA)-Loaded Mature Autologous Dendritic Cells (CapPVax) for the Treatment of Metastatic Horomone Refractory Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Castrate Resistant Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Arie Belldegrun, MD, FACS</Name></ContactNames></Trial><Trial Id="93109"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA polymerase inhibitor</Action><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>GNRH receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA intercalator</Action><Action>DNA synthesis inhibitor</Action><Action>Microtubule inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>DNA intercalator</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liposome formulation injectable</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>PEGylated formulation</Technology><Technology>Pharmaceutical carrier</Technology><Technology>Prodrug</Technology><Technology>Protein conjugated</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Suspension</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AEterna Zentaris Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Germany</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2014-06-10T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-000134-19</Identifier><Identifier>AEZS-108 in patients with LHRH receptor positive breast cancer</Identifier><Identifier>AEZS-108-049</Identifier><Identifier>NCT01698281</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including capecitabine , doxorubicin (liposomal, STEALTH), Alza , eribulin mesylate , gemcitabine , paclitaxel (albumin-bound nanoparticle, intravenous), Celgene , vinorelbine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>zoptarelin doxorubicin (intravenous, cancer), AEterna Zentaris/ Sinopharm/ Orient EuroPharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>74</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>anthracyclines or anthracenediones for the treatment of metastatic breast &lt;b&gt;cancer&lt;/b&gt; including pegylated liposomal doxorubicin (Doxil), doxorubicin, daunorubicin...of LHRH receptor confirmed by IHC on archival (or current biopsy of breast tumor or metastatic site) breast &lt;b&gt;cancer&lt;/b&gt; tissue Progressive disease after failure of one...HER2-negative) luteinizing hormone-releasing hormone receptor (LHRH-R)-positive metastatic breast &lt;b&gt;cancer&lt;/b&gt;. In February 2013, first patient was treated [ 1384879 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AEZS-108 in patients with LHRH receptor positive breast cancer: Phase II Trial of AEZS-108 in Chemotherapy Refractory Triple Negative Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with Triple Negative Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estrogen receptor </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Progesterone receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>17 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Alberto J. Montero, MD</Name><Name>Clinical trial information desk</Name><Name>G. Emons</Name><Name>Ines Altemose</Name><Name>Jenny Obando</Name><Name>Stefan Buchholz</Name><Name>Stefan Gluck</Name></ContactNames></Trial><Trial Id="34798"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Metastatic ovary cancer</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histone deacetylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Apoptosis stimulator</Action><Action>Cell differentiation stimulator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2006-09-30T00:00:00Z</DateStart><Identifiers><Identifier>7267</Identifier><Identifier>CDR0000459798</Identifier><Identifier>N01CM17107</Identifier><Identifier>N01CM62203</Identifier><Identifier>NCI-2009-00144</Identifier><Identifier>NCI-7267</Identifier><Identifier>NCT00301756</Identifier><Identifier>PHL-041</Identifier><Identifier>PMH-PHL-041</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication><Indication>Fatigue</Indication><Indication>Hypersensitivity</Indication><Indication>Intestine disease</Indication><Indication>Lymphocytopenia</Indication><Indication>Thrombosis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>belinostat (iv, cancer), Onxeo/Spectrum alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>epithelial &lt;b&gt;cancer&lt;/b&gt;, primary peritoneal carcinoma or fallopian tube &lt;b&gt;cancer&lt;/b&gt; that recurred despite initial platinumbased therapy OR micropapillary/borderline...non-evaluable. A 13.4 months median progression-free survival (PFS) was observed. In patients with epithelial ovarian &lt;b&gt;cancer&lt;/b&gt; (EOC) (n = 18), ...and partial), in patients with advanced platinum-resistant ovarian epithelial &lt;b&gt;cancer&lt;/b&gt;, primary peritoneal &lt;b&gt;cancer&lt;/b&gt;, or fallopian tube &lt;b&gt;cancer&lt;/b&gt; or micropapillary or borderline</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of CA-125 level</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of response duration</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Survival - Assessment of mean/median survival</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of antitumor activity</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Borderline or Low Malignant Potential Ovarian Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Cancer Resistant or Refractory to Non-Platinum Therapies</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase </BiomarkerName><BiomarkerName> CA-125 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>75 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Amit M. Oza</Name><Name>Amit Oza</Name></ContactNames></Trial><Trial Id="280787"><Indications><Indication>Adenocarcinoma</Indication><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Caspase-3 stimulator</Action><Action>Caspase-9 stimulator</Action><Action>FGF receptor antagonist</Action><Action>Kit tyrosine kinase inhibitor</Action><Action>PDGF receptor beta modulator</Action><Action>RET tyrosine kinase receptor family inhibitor</Action><Action>Raf 1 protein kinase inhibitor</Action><Action>Raf B protein kinase inhibitor</Action><Action>TIE tyrosine kinase receptor inhibitor</Action><Action>Tek tyrosine kinase receptor inhibitor</Action><Action>Thymidine phosphorylase inhibitor</Action><Action>Thymidylate synthase inhibitor</Action><Action>VEGF-1 receptor antagonist</Action><Action>VEGF-2 receptor antagonist</Action><Action>VEGF-3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Nucleic acid metabolism modulator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>MD Anderson Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-24T00:00:00Z</DateChangeLast><DateEnd>2021-08-31T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-0091</Identifier><Identifier>ATTACC</Identifier><Identifier>CTI_Umbrella</Identifier><Identifier>NCI-2017-00505</Identifier><Identifier>NCT01196130</Identifier><Identifier>R01CA172670</Identifier><Identifier>RP110584</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cancer Symptom Questionnaire alone</Intervention><Intervention>biomarker assessment alone</Intervention><Intervention>regorafenib alone</Intervention><Intervention>trifluridine + tipiracil hydrochloride (oral), Taiho alone</Intervention><Intervention>regorafenib plus trifluridine + tipiracil hydrochloride (oral), Taiho</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1280</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>to control the &lt;b&gt;cancer&lt;/b&gt;, and the drug was available through a separate MD Anderson clinical research study called a 'companion' drug study, doctor may ...test results may seem to show that more than one drug may help to control the &lt;b&gt;cancer&lt;/b&gt;. If so, it may be possible that patient could receive the other drug(s) under...instead either take part in a clinical research study that was not a companion study or they receive standard &lt;b&gt;cancer&lt;/b&gt; drug(s). If patient </Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Oncogenes/Oncoproteins - Assessment of K-ras/Ras mutation status</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of procedural success</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ATTACC: Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Circulating tumor DNA </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> GTPase KRas </BiomarkerName><BiomarkerName> GTPase NRas</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>132 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gastrointestinal Medical Oncology</Name><Name>Scott Kopetz, MD</Name></ContactNames></Trial><Trial Id="53749"><Indications><Indication>Small-cell lung cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligosaccharide</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-05T00:00:00Z</DateChangeLast><DateEnd>2001-11-30T00:00:00Z</DateEnd><DateStart>1998-08-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000067495</Identifier><Identifier>MSKCC-98065</Identifier><Identifier>NCI-H99-0047</Identifier><Identifier>NCT00004249</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>multivalent carbohydrate-based vaccine (cancer), Memorial Sloan-Kettering alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>keyhole limpet hemocyanin plus QS-21 ) in patients with small cell lung &lt;b&gt;cancer&lt;/b&gt;. Assess the clinical toxicities resulting from these regimens and from the immune response... Disease characteristics: Histologically confirmed small cell lung &lt;b&gt;cancer&lt;/b&gt; Must have completed initial therapy with or without radiotherapy and have achieved a...active malignancies within the past five years except nonmelanoma skin &lt;b&gt;cancer&lt;/b&gt; No clinically significant peripheral neuropathy Not pregnant or nursing Negative</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of immunological markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy Plus QS-21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Small Cell (Oat Cell) Lung Cancer (SCLC)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2001-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lee M. Krug, MD</Name></ContactNames></Trial><Trial Id="51702"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Immunostimulant</Action><Action>Prophylactic vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Natural product</Technology><Technology>Oligosaccharide</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-10T00:00:00Z</DateChangeLast><DateEnd>2019-03-31T00:00:00Z</DateEnd><DateStart>2007-03-31T00:00:00Z</DateStart><Identifiers><Identifier>06-156</Identifier><Identifier>CDR0000542903</Identifier><Identifier>MSKCC-06156</Identifier><Identifier>NCT00470574</Identifier><Identifier>P30CA008748</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Dermatological disease</Indication><Indication>Diarrhea</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Myalgia</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including QS-21 , sialyl Lea-KLH conjugate vaccine (breast cancer), MabVax Therapeutics Holdings , sialyl Lea-KLH conjugate vaccine (breast cancer), MabVax Therapeutics Holdings + QS-21</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>7</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Disease characteristics: Histologically confirmed stage IV breast &lt;b&gt;cancer&lt;/b&gt; meeting one of the following criteria: No evidence of disease Stable disease on hormonal therapy: stable disease must be present for &amp;gt;/= 2 months and include&amp;lt; 30% decrease...21 immunoadjuvantin patients with metastatic breast &lt;b&gt;cancer&lt;/b&gt;. Determine the IgG and IgM antibody response to this regimen in these patients. Determine the proportion of breast &lt;b&gt;cancer&lt;/b&gt; cells expressing this antigen in these patients. The secondary objective of</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy and QS-21 in Treating Patients With Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>144 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Teresa Ann Gilewski, MD</Name></ContactNames></Trial><Trial Id="89856"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Programmed cell death ligand 1 modulator</Action><Action>Programmed cell death protein 1 modulator</Action><Action>Ras GTPase modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Interferon gamma modulator</Action><Action>Microtubule stabilizer</Action><Action>Synergist</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intraperitoneal formulation</Technology><Technology>Intratumoral formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Oncolytics Biotech Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Canadian Cancer Trials Group</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-03-26T00:00:00Z</DateChangeLast><DateEnd>2018-02-14T00:00:00Z</DateEnd><DateStart>2012-07-30T00:00:00Z</DateStart><Identifiers><Identifier>I213</Identifier><Identifier>IND 213</Identifier><Identifier>NCT01656538</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Nausea</Indication><Indication>Neoplasm</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>paclitaxel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>paclitaxel plus pelareorep (cancer), Oncolytics</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>81</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>evaluated the safety and tolerability of intravenous pelareorep in combination with chemotherapy in &lt;b&gt;cancer&lt;/b&gt; patients. Fever (65 to 46 versus 11 to 8%), chills (62...with a history of other malignancies, except for adequately treated non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; or solid tumors curatively treated with no evidence of disease for more...lactating. Men must be surgically sterile or use a barrier method of contraception Concurrent treatment with other investigational drugs or anti-&lt;b&gt;cancer&lt;/b&gt; therapy</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>AKT-interacting protein </BiomarkerName><BiomarkerName> Adenomatous polyposis coli protein </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Cellular tumor antigen p53 </BiomarkerName><BiomarkerName> Circulating Tumor Cells </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Mast/stem cell growth factor receptor </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </BiomarkerName><BiomarkerName> Serine-protein kinase ATM</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-11-18T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Susan Ellard</Name><Name>Vanessa Bernstein</Name></ContactNames></Trial><Trial Id="40305"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Placenta growth factor ligand inhibitor</Action><Action>VEGF-A ligand inhibitor</Action><Action>VEGF-B ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Metastasis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology><Technology>Receptor fusion</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-23T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000491314</Identifier><Identifier>NCCTG-N0537</Identifier><Identifier>NCI-2012-01827</Identifier><Identifier>NCT00369655</Identifier><Identifier>U10CA025224</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Hypertension</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>aflibercept (intravenous, cancer), Regeneron/Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>to: Assess the antitumor activity of VEGF Trap , in terms of tumor response rate, in patients with metastatic breast &lt;b&gt;cancer&lt;/b&gt; who have received &amp;lt;/= 2 prior chemotherapy regimens for metastatic disease, including a taxane and/or anthracycline. Assess... This phase II trial was studying how well VEGF Trap works in treating patients with metastatic breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>VEGF Trap in Treating Patients With Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Edith Perez</Name></ContactNames></Trial><Trial Id="39606"><Indications><Indication>Hormone refractory prostate cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2009-03-31T00:00:00Z</DateEnd><DateStart>2000-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000068598</Identifier><Identifier>MSKCC-99062</Identifier><Identifier>NCI-G01-1941</Identifier><Identifier>NCT00016146</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>GPI-0100 alone</Intervention><Intervention>MUC2-KLH conjugate vaccine (prostate cancer), Memorial Sloan-Kettering alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>34</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>with adjuvant GPI-0100 in patients with biochemically relapsed prostate &lt;b&gt;cancer&lt;/b&gt;; assess post-immunization changes in prostate-specific antigen levels and other objective... Disease characteristics: Histologically confirmed prostate &lt;b&gt;cancer&lt;/b&gt; Biochemically progressive disease after primary surgery or radiotherapy with or without neoadjuvant...other prior malignancy within the past five years except nonmelanoma skin &lt;b&gt;cancer&lt;/b&gt; No positive stool guaiac except hemorrhoids or history of documented radiation-induced</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of antibody titers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Clinical Assessments - Assessment of liver function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Early Stage/Localized Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Locally Advanced Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage I Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage III Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with radiotherapy resistant disease</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Surgical failure subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>104 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Susan Slovin, MD, PhD</Name></ContactNames></Trial><Trial Id="163660"><Indications><Indication>Metastatic rectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hypoxia inducible factor-1 alpha inhibitor</Action><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Dare Bioscience Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>UNC Lineberger Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-09T00:00:00Z</DateChangeLast><DateEnd>2021-09-16T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>LCCC 1315</Identifier><Identifier>NCT02010567</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Colitis</Indication><Indication>Constipation</Indication><Indication>Dermatitis</Indication><Indication>Diarrhea</Indication><Indication>Fatigue</Indication><Indication>Hypokalemia</Indication><Indication>Hypophosphatemia</Indication><Indication>Lymphocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Intensity modulated radiation therapy (1.8 Gy) alone</Intervention><Intervention>surgical resection alone</Intervention><Intervention>Variable regimens including capecitabine , capecitabine + CRLX-101 + radiation therapy , poly-cyclodextrin-PEG-camptothecin-conjugate (nanoparticle/intravenous, cancer), BlueLink Pharmaceuticals</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>CRLX-101 plus capecitabine and radiation therapy (XRT) in patients with rectal &lt;b&gt;cancer&lt;/b&gt; using the traditional 3 + 3 dose-escalation design. Adverse events (AEs) would...the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal &lt;b&gt;cancer&lt;/b&gt; for a total of 5 to 6 weeks, depending on the total radiation...active' second malignancy other than non-melanoma skin cancers, non-invasive bladder &lt;b&gt;cancer&lt;/b&gt;, 'low-risk' adenocarcinoma of the prostate and carcinoma in situ of</Teaser><TrialCategories><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of clinical/pathological response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with resectable colorectal cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Hypoxia-inducible factor 1 alpha </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>92 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Andrew Wang, MD</Name></ContactNames></Trial><Trial Id="230391"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Metastatic ovary cancer</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon agonist</Action><Action>TLR-3 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Corticosteroid agonist</Action><Action>IL release stimulator</Action><Action>Immunostimulant</Action><Action>Natural killer cell stimulator</Action><Action>T-lymphocyte stimulator</Action><Action>TNF release modulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>The Ovarian Cancer Research Fund</Company></CompaniesCollaborator><CompaniesSponsor><Company>Abramson Cancer Center of the University of Pennsylvania</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-05-30T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02452775</Identifier><Identifier>UPCC 40814</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>OC-L vaccine (cancer), University of Pennsylvania alone</Intervention><Intervention>Variable regimens including OC-L vaccine (cancer), University of Pennsylvania , Poly-ICLC , montanide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Subject has primary ovarian (including low malignant potential), fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt; FIGO stage III or IV defined surgically at the completion of initial abdominal surgery Subject has had cytoreductive surgery and has...agents, montanide and Poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine ( OC-L vaccine ) administered&amp;nbsp; with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Autologous OC-L Vaccine and Ovarian Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Borderline or Low Malignant Potential Ovarian Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Fallopian Tube Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Peritoneal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-05-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="51433"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2009-11-30T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000563948</Identifier><Identifier>NCT00528775</Identifier><Identifier>RPCI-I-98707</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HPPH photodynamic therapy (cancer), Roswell Park alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>6</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>photodynamic therapy in patients with advanced obstructing endobronchial non-small cell lung &lt;b&gt;cancer&lt;/b&gt;. The secondary objectives of the study were: To determine palliation...Disease characteristics: Biopsy confirmed advanced obstructing endobronchial non-small cell lung &lt;b&gt;cancer&lt;/b&gt; May have squamous cell carcinoma, adenocarcinoma, or large cell...therapy: Any type of prior therapy (eg, chemotherapy or radiotherapy) for lung &lt;b&gt;cancer&lt;/b&gt; allowed At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Biomarkers - Assessment of inflammatory/oxidative markers</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Biomarkers - Assessment of signaling pathways</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms - Assessment by Pulmonary Symptom Scale</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of apoptosis markers</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pulmonary Function - Assessment of pulmonary symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Signal transducer and activator of transcription 3</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Todd L. Demmy, MD</Name></ContactNames></Trial><Trial Id="226987"><Indications><Indication>Liver tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>LIVER CANCER CTC 001</Identifier><Identifier>NCT02416635</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>DC-CIK alone</Intervention><Intervention>Flow cytometry (FCM) alone</Intervention><Intervention>RT-PCR alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>DC-CIK treatment. Blood wil be drawn by vein puncture from patients with liver &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers will be used to... Patients with other primary tumor except liver &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...to 75 years Karnofsky performance status &amp;gt; 60 Diagnosis of liver &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><BiomarkerNames><BiomarkerName>Circulating Tumor Cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="181840"><Indications><Indication>Bladder cancer</Indication></Indications><CompaniesSponsor><Company>Hospital Vall D'Hebron</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-02-17T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2005-04-30T00:00:00Z</DateStart><Identifiers><Identifier>HIGHGRADET1 BLADDER CANCER HVH</Identifier><Identifier>NCT02113501</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bacillus de Calmette-Guerin (BCG) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients with HGT1a bladder &lt;b&gt;cancer&lt;/b&gt; would receive standard Bacillus de Calmette-Guerin (BCG) treatment and maintenance followed by conventional follow-up (cystoscopy... HGT1 bladder &lt;b&gt;cancer&lt;/b&gt; at initial diagnosis and after a complete ...bladder &lt;b&gt;cancer&lt;/b&gt; based on substaging (depth of lamina propria invasion). The main hypothesis was that HGT1a bladder &lt;b&gt;cancer&lt;/b&gt; could spare a second endoscopic</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Survival - Assessment of disease specific survival (DSS)</EndpointIndex></EndpointIndex><TitleDisplay>Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: A Prospective, Observational, Cohort Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 1 Bladder Cancer (G1)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>104 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Anna Orsola, MD</Name></ContactNames></Trial><Trial Id="157304"><Indications><Indication>Uterine cervix tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AKT protein kinase inhibitor</Action><Action>MEK-1 protein kinase inhibitor</Action><Action>MEK-2 protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Comprehensive Cancer Network</Company><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Dana-Farber Cancer Institute Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-03T00:00:00Z</DateChangeLast><DateEnd>2017-11-30T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>13-334</Identifier><Identifier>NCT01958112</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>trametinib plus uprosertib + trametinib (cancer), Laekna Therapeutics</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>14</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>research study. Many of these tests and procedures would likely to be part of regular &lt;b&gt;cancer&lt;/b&gt; care and may be done even if it turns out that the patient does not take...patient's &lt;b&gt;cancer&lt;/b&gt; to see if researchers can learn more about the patient's type of &lt;b&gt;cancer&lt;/b&gt; and understand how trametinib and...and proteins in the patient's blood to compare them with those seen in their &lt;b&gt;cancer&lt;/b&gt;. This would be drawn before the patient begin taking the study drug. These</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Tumor Response</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Oncogenes/Oncoproteins - Assessment of phosphorylated phosphatidylinositol 3-kinase (PI3K) gene status</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Uterine cervix tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>GSK-1120212 + GSK-2141795 for Cervical Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Papillomavirus infection - Subjects with Cervical Cancer</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Advanced/Metastatic Cervical Cancer (Stage IVB)</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Recurrent/Relapsed Cervical Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood cells </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Mitogen Activated Protein Kinases </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ursula A Matulonis, MD</Name></ContactNames></Trial><Trial Id="230254"><Indications><Indication>Renal tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02450448</Identifier><Identifier>RENAL CANCER CTC 001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cryosurgery alone</Intervention><Intervention>Dendritic cell-cytokine-induced killers alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>tetraacetic acid (EDTA)-blood was drawn by vein puncture from patients with renal &lt;b&gt;cancer&lt;/b&gt; and healthy volunteers. The blood of the healthy volunteers will be used to evaluate... Patients with other primary tumor except renal &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 75 years Karnofsky performance status&amp;gt; 60 Diagnosis of renal &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Others - Healthy Subjects</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage II Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage III Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Mononuclear leukocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="246391"><Indications><Indication>Cancer pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NGF receptor antagonist</Action><Action>Nerve growth factor ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Czechoslovakia</Country><Country>Czech Republic</Country><Country>Sweden</Country><Country>Australia</Country><Country>Chile</Country><Country>Serbia</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Austria</Country><Country>UK</Country><Country>Romania</Country><Country>Spain</Country><Country>Israel</Country><Country>Germany</Country><Country>France</Country><Country>Argentina</Country><Country>Slovakia</Country><Country>Japan</Country><Country>Poland</Country><Country>South Korea</Country><Country>China</Country></Countries><DateChangeLast>2019-03-15T00:00:00Z</DateChangeLast><DateEnd>2021-01-12T00:00:00Z</DateEnd><DateStart>2015-10-28T00:00:00Z</DateStart><Identifiers><Identifier>2013-002223-42</Identifier><Identifier>A4091061</Identifier><Identifier>CANCER PAIN PH 3 SC STUDY</Identifier><Identifier>JapicCTI-163141</Identifier><Identifier>NCT02609828</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tanezumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>155</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>classified as neuropathical, visceral or unknown in nature, has resulted from prior &lt;b&gt;cancer&lt;/b&gt; therapy, is due to infection or is otherwise not predominantly related to a...female, &amp;gt;/= 18 years of age Weight &amp;gt;/= 40 kg at screening &lt;b&gt;Cancer&lt;/b&gt;&amp;nbsp;diagnosed as having metastasized to&amp;nbsp;bone&amp;nbsp;or&amp;nbsp;multiple&amp;nbsp;myeloma Imaging confirmation of bone metastasis...metastasis &lt;b&gt;cancer&lt;/b&gt; pain site Patient's Global Assessment of &lt;b&gt;Cancer&lt;/b&gt; Pain of 'fair', 'poor' or 'very poor</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Antibodies</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain - Numerical Rating Scale (NRS-11, NRS-101)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Physical Examination - Assessment of anthropometric measurements</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Symptom Distress Score (SDS)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase III Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Breast Cancer Subjects with Bone Metastasis</PatientSegment><PatientSegment>Cancer supportive care - Cancer/Treatment-related Pain</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-03-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>62 Months</TrialDuration><NumberOfSites>124</NumberOfSites><ContactNames><Name>Agnieszka Kluczna, MD</Name><Name>Alejandro Orts Castro, MD</Name><Name>Ancor Serrano Afonso, MD</Name><Name>Andras Telekes, MD</Name><Name>Andrzej Stachowiak, MD</Name><Name>Burkhard Gustorff, MD</Name><Name>Carlos Jara Sanchez, MD</Name><Name>Carmen Crihana, MD</Name><Name>Christos Karapetis, MD</Name><Name>ClinicalTrials.gov call Center</Name><Name>Concepci√≥n P√©rez Hern√°ndez, MD</Name><Name>C√©sar Margarit Ferri, MD</Name><Name>Dan Lungulescu, MD</Name><Name>Dirk Forstmeyer, MD</Name><Name>Felipe Cruz, MD</Name><Name>Fernanda Damian, MD</Name><Name>Georg Nuhr, MD</Name><Name>Giuliano Borges, MD</Name><Name>Han Yong Choi, MD</Name><Name>Hedviga Jakubikova, MD</Name><Name>Jinsoo Chung, MD</Name><Name>Jiri Klecka, MD</Name><Name>Jitka Fricova, MD</Name><Name>Joo Hyuk Sohn, MD</Name><Name>Juan C√∫ndom, MD</Name><Name>Jung Hye Kwon, MD</Name><Name>Keon Uk Park, MD</Name><Name>Laszlo Landherr, MD</Name><Name>Lee Na Teo, MD</Name><Name>Lubomira Nemcikova, MD</Name><Name>Ludmila Koch, MD</Name><Name>Lynn Maeda, MD</Name><Name>Maciej Sopata, MD</Name><Name>Magdalena Korozan, MD</Name><Name>Marcin Janecki, MD</Name><Name>Maria Goretti Pazos Gonzalez, MD</Name><Name>Maria Salete Nascimento, MD</Name><Name>Marie Fallon, MD</Name><Name>Martin Smakal, MD</Name><Name>Medgyasszay Balazs, MD</Name><Name>Michael Franco, MD</Name><Name>Michael Schenker, MD</Name><Name>Ondrej Slama, MD</Name><Name>Patricia Milhomem, MD</Name><Name>Patricia Santi, MD</Name><Name>Pavol Demo, MD</Name><Name>Peter Barrett-Lee, MD</Name><Name>Petra Panovcova, MD</Name><Name>Pfizer CT.gov Call Center</Name><Name>Pfizer Inc</Name><Name>Pfizer Japan Inc.</Name><Name>Philippe Poulain, MD</Name><Name>Ra√∫l Sala, MD</Name><Name>Roxana Ioana Scheusan, MD</Name><Name>Rudolf Likar, MD</Name><Name>Sandra Serrano, MD</Name><Name>Susanne Costa, MD</Name><Name>Tae-Yong Kim, MD</Name><Name>Tam√°s Pint√©r, MD</Name><Name>Tatiana Pietrzynska, MD</Name><Name>Thomas Cuvier, MD</Name><Name>Tiago Biachi de Castria, MD</Name><Name>Tibor Csoszi, MD</Name><Name>Viliam Cibik, MD</Name><Name>Zbigniew Nowecki, MD</Name><Name>Zsofia Polya, MD</Name></ContactNames></Trial><Trial Id="366804"><Indications><Indication>Surgical procedure</Indication></Indications><CompaniesSponsor><Company>Instituto Nacional de Cancer, Brazil</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-01-21T00:00:00Z</DateChangeLast><DateEnd>2020-02-01T00:00:00Z</DateEnd><DateStart>2018-02-18T00:00:00Z</DateStart><Identifiers><Identifier>Exercise</Identifier><Identifier>NCT03796845</Identifier><Identifier>SHOULDER EXERCISE CANCER</Identifier></Identifiers><InterventionsControlDisplay><Intervention>restricted shoulder movement alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>unrestricted shoulder movement alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>breast &lt;b&gt;cancer&lt;/b&gt; at Hospital do &lt;b&gt;Cancer&lt;/b&gt; III (HCIII-INCA) located in Rio de Janeiro. All patients admitted for surgical treatment at the institution and during the study...breast &lt;b&gt;cancer&lt;/b&gt; Reconstruction surgery Functional alteration in upper limbs prior to diagnosis of breast &lt;b&gt;cancer&lt;/b&gt; Illiterate women who are not able... Women aged 18 and over Indication of curative surgical treatment for breast &lt;b&gt;cancer&lt;/b&gt; axillary approach at Hospital do C√¢ncer III / INCA</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Morbidity Rates</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Exercise: Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Cancer supportive care - Surgery induced toxicity</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Shoulder motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Anke Bergman</Name><Name>Anke Bergmann</Name><Name>Clarice C Teodozio</Name><Name>Clarice Gomes C Teodozio</Name></ContactNames></Trial><Trial Id="318633"><Indications><Indication>Biliary cancer</Indication><Indication>Metastasis</Indication><Indication>Metastatic colorectal cancer</Indication><Indication>Metastatic esophageal cancer</Indication><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PARP inhibitor</Action><Action>Poly ADP ribose polymerase 1 inhibitor</Action><Action>Poly ADP ribose polymerase 2 inhibitor</Action><Action>Poly ADP ribose polymerase 3 inhibitor</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Endocrine diagnostic agent</Action><Action>Folic acid analog</Action><Action>Gastrointestinal diagnostic agent</Action><Action>Neoplasm diagnostic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liposome formulation</Technology><Technology>Nanoparticle formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Academic and Community Cancer Research United</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-05T00:00:00Z</DateChangeLast><DateEnd>2022-12-31T00:00:00Z</DateEnd><DateStart>2018-11-02T00:00:00Z</DateStart><Identifiers><Identifier>ACCRU-GI-1603</Identifier><Identifier>ACCRU-GI-1603</Identifier><Identifier>NCI-2017-01976</Identifier><Identifier>NCT03337087</Identifier><Identifier>P30CA015083</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including calcium levofolinate , fluorouracil , irinotecan sucrosofate (nanoliposomal, cancer), PharmaEngine/Merrimack/Shire , rucaparib camsylate (oral, solid tumors), Clovis</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>propria]); Note: all &lt;b&gt;cancer&lt;/b&gt; treatments for those distinct in a primary site other than &lt;b&gt;cancer&lt;/b&gt; of origin must be completed &amp;gt;/= 3 years prior...of prior therapy in the metastatic setting Patients with metastatic disease from biliary tract &lt;b&gt;cancer&lt;/b&gt; who received no more than one line of prior...pancreatic &lt;b&gt;cancer&lt;/b&gt; who received no more than one line of prior therapy in the metastatic setting Patients with metastatic disease from gastroesophageal &lt;b&gt;cancer&lt;/b&gt; who received </Teaser><TrialCategories><Category>Diagnostic</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of anti-tumor activity</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Tumor Related Parameters - Assessment of change in lesion size/number</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Tumor Suppressor Genes/Proteins</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Tumor Suppressor Genes/Proteins</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Esophagus tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Esophagus tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Esophagus tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Tumor Suppressor Genes/Proteins</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Tumor Suppressor Genes/Proteins - Assessment of Breast Cancer Gene (BRCA)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Pancreas tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Pancreas tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pancreas tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Pancreas tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium and Rucaparib Phosphate in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease - Subjects with unresectable Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Adenocarcinoma of Esophagus</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Gastro-esophageal Junction Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Unresectable Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Treatment Naive Subjects</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Cholangiocarcinoma/Bile Duct Cancer - Subjects with metastatic/advanced cholangiocarcinoma</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Cholangiocarcinoma/Bile Duct Cancer - Subjects with progressive/treatment refractory cholangiocarcinoma</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Unresectable Hepato-biliary Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Treatment Naive Subjects</PatientSegment><PatientSegment>Pancreas tumor - Pancreatic cancer with mutated BRCA2 gene</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Adenocarcinoma of Pancreas</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Unresectable Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with gene variants - BRCA1_HUMAN_Mutation</PatientSegment><PatientSegment>Pancreas tumor - Subjects with gene variants - BRCA2_HUMAN_Mutation</PatientSegment><PatientSegment>Pancreas tumor - Subjects with gene variants - PALB2_HUMAN_Mutation</PatientSegment><PatientSegment>Pancreas tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein </BiomarkerName><BiomarkerName> Partner and localizer of BRCA2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Christina S. Wu</Name><Name>Clinical Trial Referral Office</Name><Name>Clinical Trials Referral Office</Name><Name>Ignacio Garrido-Laguna</Name><Name>Susan Sharry</Name><Name>Tanios Bekaii-Saab</Name><Name>Tanios S. Bekaii-Saab</Name><Name>Wen Wee MA</Name></ContactNames></Trial><Trial Id="35825"><Indications><Indication>Metastatic breast cancer</Indication><Indication>Metastatic ovary cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PARP inhibitor</Action><Action>Poly ADP ribose polymerase 1 inhibitor</Action><Action>Poly ADP ribose polymerase 2 inhibitor</Action><Action>Poly ADP ribose polymerase 3 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Cancer Research UK</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-01-03T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2007-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000593558</Identifier><Identifier>CRUK-PARP/BRCA</Identifier><Identifier>CRUK-PH2-052</Identifier><Identifier>EU-20842</Identifier><Identifier>EUDRACT-2006-002348-27</Identifier><Identifier>NCT00664781</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Fatigue</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>rucaparib camsylate (oral, solid tumors), Clovis alone</Intervention><Intervention>rucaparib phosphate (iv, solid tumors), Clovis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>78</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>inhibitor AG-014699 in patients with locally advanced or metastatic breast or advanced ovarian &lt;b&gt;cancer&lt;/b&gt; shown to express the BRCA 1 or 2 mutations. To evaluate the toxicity...status ( BRCA 1 versus BRCA 2). In addition, patient with high-grade serous ovarian &lt;b&gt;cancer&lt;/b&gt; could be enrolled into stage 1 of the study. All patients enrolled would recieve...breast &lt;b&gt;cancer&lt;/b&gt; or advanced ovarian &lt;b&gt;cancer&lt;/b&gt; or high-grade serous ovarian &lt;b&gt;cancer&lt;/b&gt; (for stage I only) Must meet one of the following criteria: Proven a</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of DNA double strand break repair pathway function</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of DNA repair enzyme status</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers - Assessment of Poly (ADP-ribose) polymerase (PARP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Tumor Suppressor Genes/Proteins - Assessment of Breast Cancer Gene (BRCA)</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of gene polymorphisms</EndpointIndex><EndpointIndex>Breast tumor - Protocol Specified Other Endpoints - Assessment of Antitumor Activity</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of BRCA1/BRCA2</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of antitumor activity</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Magnetic Resonance Imaging (MRI)</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Computerized tomography(CT) findings</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Rucaparib (CO-338; Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - BRCA1_HUMAN_Mutation</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - BRCA2_HUMAN_Mutation</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Ovarian Cancer Subjects with BRCA1 or BRCA2 Expression</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein </BiomarkerName><BiomarkerName> Collagen alpha-2(XI) chain </BiomarkerName><BiomarkerName> Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Cytochrome P450 3A5</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>85 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Ruth Plummer</Name></ContactNames></Trial><Trial Id="347529"><Indications><Indication>Breast tumor</Indication></Indications><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2019-01-10T00:00:00Z</DateChangeLast><DateEnd>2019-09-30T00:00:00Z</DateEnd><DateStart>2019-01-20T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER</Identifier><Identifier>NCT03598660</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enzyme linked immuno sorbent assay alone</Intervention><Intervention>real time PCR alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Breast &lt;b&gt;cancer&lt;/b&gt; patients before surgery who are admitted to the South Egypt &lt;b&gt;Cancer&lt;/b&gt; Institute, Surgery Department, Assiut University will be included and observed... Breast &lt;b&gt;cancer&lt;/b&gt; patients before surgery who are admitted to the South Egypt &lt;b&gt;Cancer&lt;/b&gt; Institute, Surgery Department, Assiut University... The purpose of the study is to evaluate role of sorcin and annexin A3 in breast &lt;b&gt;cancer&lt;/b&gt; patients.</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of gene expression profile/signature</EndpointIndex><EndpointIndex>Breast tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Role of Sorcin and Annexin A3 in Breast Cancer Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Annexin A3 </BiomarkerName><BiomarkerName> Sorcin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-08-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>reham elmahdy</Name></ContactNames></Trial><Trial Id="355105"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>Cytosine DNA methyltransferase inhibitor</Action><Action>HLA class I antigen A-2 alpha modulator</Action><Action>HLA class II antigen modulator</Action><Action>Interleukin-2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer hormone</Action><Action>Antiviral</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Autologous stem cell therapy</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Haematopoietic stem cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Lymphocyte</Technology><Technology>Lymphocyte cell therapy</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>T-lymphocyte</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-30T00:00:00Z</DateChangeLast><DateEnd>2020-10-01T00:00:00Z</DateEnd><DateStart>2019-01-24T00:00:00Z</DateStart><Identifiers><Identifier>I 287616</Identifier><Identifier>NCI-2018-01758</Identifier><Identifier>NCT03691376</Identifier><Identifier>P30CA016056</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including aldesleukin , anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy + dnTGFbetaRII tumor infiltrating lymphocytes (solid tumor), Roswell Park Comprehensive Cancer Center , decitabine , hematopoietic stem cell-derived anti-NY-ESO-1/HLA-DP4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy (ovarian/fallopian tube/primary peritoneal cancer), Roswell Park Comprehensive Cancer Center , melphalan</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>HSC iv on day 0 and autologous anti-NY-ESO-1 TCR T-cell therapy (CD8-positive, &lt;b&gt;cancer&lt;/b&gt;), Roswell/NCI iv on days 3 and 90. Patients will also receive aldesleukin (Proleukin...to agents used in the study Prior malignancy (except non melanoma skin &lt;b&gt;cancer&lt;/b&gt;) within three years Uncontrolled intercurrent illness including, but not limited to...peritoneal &lt;b&gt;cancer&lt;/b&gt; that has come back or does not respond to treatment. Primary objective is to assess the safety and feasibility of</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of response duration</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Ovary tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Sensitive Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with gene variants - HLA-A_HUMAN_A*02010101</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Fallopian Tube Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with specific disease - Subjects with Peritoneal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kunle Odunsi</Name></ContactNames></Trial><Trial Id="333767"><Indications><Indication>Breast tumor</Indication></Indications><CompaniesCollaborator><Company>Bayer AG</Company><Company>Korean Society of Breast Imaging &amp; Korean Society company</Company></CompaniesCollaborator><CompaniesSponsor><Company>Seoul National University Hospital</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2019-03-05T00:00:00Z</DateChangeLast><DateEnd>2022-05-31T00:00:00Z</DateEnd><DateStart>2018-05-01T00:00:00Z</DateStart><Identifiers><Identifier>AB-MR FOR SECOND BREAST CANCER</Identifier><Identifier>NCT03475979</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Abbreviated breast MRI alone</Intervention><Intervention>Mammography alone</Intervention><Intervention>Ultrasound alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1564</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Patients who undergo second breast &lt;b&gt;cancer&lt;/b&gt; surveillance with AB-MR or ultrasound (US) in addition to annual mammography will be observed....second breast &lt;b&gt;cancer&lt;/b&gt; or regional/distant metastasis Systemic chemotherapy for any &lt;b&gt;cancer&lt;/b&gt; Pregnant or lactating Contraindication to breast MRI with contrast enhancement... Women aged between 25 years and&amp;nbsp;75&amp;nbsp;years&amp;nbsp;with a personal history&amp;nbsp;of breast &lt;b&gt;cancer&lt;/b&gt; BRCA mutation test done&amp;nbsp; (meeting any of the</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Molecular and Histopathological Characteristics</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Assessment by ultrasonography</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Magnetic resonance spectroscopic imaging (MRSI)</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Mammography</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - BRCA Mutation Positive Breast Cancer Subjects - BRCA1-positive breast cancer</PatientSegment><PatientSegment>Breast tumor - BRCA Mutation Positive Breast Cancer Subjects - BRCA2-positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIB Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIC Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - BRCA1_HUMAN_Mutation</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - BRCA2_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> Breast cancer type 2 susceptibility protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Woo Kyung Moon, MD, PhD</Name><Name>Woo Moon</Name></ContactNames></Trial><Trial Id="28569"><Indications><Indication>Bladder cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Jonsson Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2015-11-02T00:00:00Z</DateChangeLast><DateEnd>2006-07-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000377681</Identifier><Identifier>NCT00088946</Identifier><Identifier>P30CA016042</Identifier><Identifier>UCLA-0301091-03</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Polyphenon E (oral) plus erlotinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>bladder &lt;b&gt;cancer&lt;/b&gt; recurrence and/or progression in patients treated with these drugs. Determine the risk of clinical bladder &lt;b&gt;cancer&lt;/b&gt; progression in...resection Prior treatment with experimental drugs, high dose steroids, or with any other &lt;b&gt;cancer&lt;/b&gt; treatment within 4 weeks prior to the first dose of study drug and for...smokers and have ceased smoking at study entry Participants with any previous history of prior &lt;b&gt;cancer&lt;/b&gt; diagnosis of Grade 1, 2, or 3, Ta or T1 papillary TCC, or</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence - Assessment of recurrence rate</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Erlotinib and Green Tea Extract (Polyphenon E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 1 Bladder Cancer (G1)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Histologic Grade 2 Bladder Cancer (G2)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage I Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0a or non-invasive papillary carcinoma (Ta)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer - TNM Stage 0is or carcinoma in situ (Tis)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Arie Belldegrun</Name></ContactNames></Trial><Trial Id="31014"><Indications><Indication>Anal tumor</Indication><Indication>Metastatic esophageal cancer</Indication><Indication>Metastatic head and neck cancer</Indication><Indication>Penis tumor</Indication><Indication>Uterine cervix tumor</Indication><Indication>Vulvar intraepithelial neoplasia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Protein subunit vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-03T00:00:00Z</DateChangeLast><DateStart>1995-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000064330</Identifier><Identifier>NCI-95-C-0154</Identifier><Identifier>NCI-T94-0134N</Identifier><Identifier>NCT00001441</Identifier><Identifier>NCT00019110</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HPV-16 E7 vaccine (cancer), NCI alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>cervical &lt;b&gt;cancer&lt;/b&gt; not previously treated with appropriate radiotherapy; stage IV or recurrent cervical &lt;b&gt;cancer&lt;/b&gt;; or other advanced tumors that harbor...cervical &lt;b&gt;cancer&lt;/b&gt;) No history of CNS metastases Patient characteristics: Age: Over 18 years Performance status: ECOG 0 to 1 Life expectancy: &amp;gt; 3 months...the past 6 months No other active malignancy except basal cell skin &lt;b&gt;cancer&lt;/b&gt; Not pregnant or nursing Negative pregnancy test Fertile patients must use effective</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anal tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Anal tumor - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Basal cell carcinoma - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Basal cell carcinoma - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Basal cell carcinoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immune Response - Assessment of cell-mediated immunity</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Safety and Tolerability - Assessment of systemic reactions</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Immune Response - Cellular immune response</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Tumor Response</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Immune Function</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Anal tumor - Subjects at risk of developing disease - Subjects with HPV-associated anal cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with Locally Advanced Anal Cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with Relapsed/Recurrent Anal Cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with Stage IIIA Anal Cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with Stage IIIB Anal Cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with Stage IV Anal Cancer</PatientSegment><PatientSegment>Anal tumor - Subjects with gene variants - HLA-A_HUMAN_A*02010101</PatientSegment><PatientSegment>Basal cell carcinoma - Subjects with Advanced Basal Cell Carcinoma (BCC)</PatientSegment><PatientSegment>Basal cell carcinoma - Subjects with Relapsed Basal Cell Carcinoma (BCC)</PatientSegment><PatientSegment>Basal cell carcinoma - Subjects with gene variants - HLA-A_HUMAN_A*02010101</PatientSegment><PatientSegment>Head and neck tumor - Subjects at risk of developing disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Locally Advanced Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage III Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with gene variants - HLA-A_HUMAN_A*02010101</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects Received/Scheduled for Other Therapies</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects Received/Scheduled for Other Therapies - Subjects received/scheduled for immunotherapy</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions - Subjects with cervical cancer/cervical dysplasia</PatientSegment><PatientSegment>Human Papillomavirus Vaccine - Subjects with History of Human Papillomavirus(HPV) Infection/Related Conditions - Subjects with other human Papillomavirus(HPV) related cancers</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Anal Cancer</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Cervical Cancer</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Oropharyngeal/Head and Neck Cancer</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Penile Cancer</PatientSegment><PatientSegment>Papillomavirus infection - Subjects with Vulvar Cancer</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Advanced/Metastatic Cervical Cancer (Stage IVB)</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Locally Advanced Cervical Cancer (Stage IIB - IVA)</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Locally Advanced Cervical Cancer (Stage IIB - IVA) - Subjects with Stage III cervical cancer</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Recurrent/Relapsed Cervical Cancer</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with gene variants - HLA-A_HUMAN_A*02010101</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HLA class I histocompatibility antigen, A alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>7</NumberOfSites><ContactNames><Name>Barry L. Gause, MD</Name></ContactNames></Trial><Trial Id="135946"><Indications><Indication>Metastatic rectal cancer</Indication></Indications><CompaniesSponsor><Company>Berlin Cancer Society</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Austria</Country></Countries><DateChangeLast>2017-07-05T00:00:00Z</DateChangeLast><DateStart>2004-01-15T00:00:00Z</DateStart><Identifiers><Identifier>2004-001606-27</Identifier><Identifier>BRCT (Berlin Rectal Cancer Trial)</Identifier><Identifier>ISRCTN56463377</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>5-fluorouracil alone</Intervention><Intervention>radiotherapy alone</Intervention><Intervention>total mesorectal excision alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>760</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>of metastatic disease or recurrent rectal tumor Any previous chemotherapy or radiotherapy, and any investigational treatment for rectal &lt;b&gt;cancer&lt;/b&gt; Concurrent uncontrolled medical conditions Pregnancy...colorectal &lt;b&gt;cancer&lt;/b&gt; (hereditary non-polyposis colorectal &lt;b&gt;cancer&lt;/b&gt; [HNPCC] and familial adenomatous polyposis [FAP]) Medical or psychiatric conditions that...or better Histological diagnosis of adeno- or mucinous carcinoma of rectum Primary rectal &lt;b&gt;cancer&lt;/b&gt;: Maximum 12 cm above dentate line (upper limit) Staged T2N+ or</Teaser><TrialCategories><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of tumor resectability</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Functional assessment of bowel</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BRCT (Berlin Rectal Cancer Trial): Pre-operative Short-course Radiotherapy Versus Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (UT2N+, uT3N-/+)</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Peter Schlag</Name></ContactNames></Trial><Trial Id="292539"><Indications><Indication>Cancer</Indication></Indications><CompaniesSponsor><Company>Sun Yat-Sen University</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2021-05-01T00:00:00Z</DateEnd><DateStart>2017-06-01T00:00:00Z</DateStart><Identifiers><Identifier>CANCER SCREENING</Identifier><Identifier>NCT03096938</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bisulfite conversion alone</Intervention><Intervention>Cell-free DNA extraction alone</Intervention><Intervention>deep sequencing alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15000</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>investigator should preclude participation in the study Subject has a history of &lt;b&gt;cancer&lt;/b&gt; Participation in any 'interventional' clinical study within the previous 30 days... Subject is average risk for development of &lt;b&gt;cancer&lt;/b&gt; Subject able and willing to undergo screening test within 90 days of enrollment Subject is 40 to 74 years ... The purpose of this study is to evaluate the role of cell-free DNA methylation markers in &lt;b&gt;cancer&lt;/b&gt; screening.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Solid tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Cell-free DNA Methylation Markers for Cancer Screening</TitleDisplay><PatientSegmentTerms><PatientSegment>Solid tumor - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cell-free DNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hui-yan Luo, MD.PhD.</Name><Name>Rui-hua Xu, MD.PhD.</Name></ContactNames></Trial><Trial Id="231245"><Indications><Indication>Lung tumor</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02449122</Identifier><Identifier>Nano drug lung cancer</Identifier></Identifiers><InterventionsControlDisplay><Intervention>HepaSphere drug microspheres alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Gemzar + compound glycyrrhizin nano drug alone</Intervention><Intervention>digital subtraction angiography alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>lung &lt;b&gt;cancer&lt;/b&gt; patients would receive drug microspheres (HepaSphere microspheres) interventional therapy using digital subtraction angiography. Arm 3: lung &lt;b&gt;cancer&lt;/b&gt; patients who... Patients with other primary tumor except lung &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...Age: 18 to 80 Karnofsky performance status&amp;gt; 60 Diagnosis of lung &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor, nodes</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 1 year</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Nano Drug Interventional Therapy Using Digital Subtraction Angiography (DSA) for Lung Carcinoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Early Stage Lung Cancer - Subjects with stage II lung cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Niu, PhD</Name></ContactNames></Trial><Trial Id="231212"><Indications><Indication>Pancreas tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2017-07-21T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NANO DRUG PANCREATIC CANCER</Identifier><Identifier>NCT02449135</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HepaSphere Microspheres alone</Intervention><Intervention>digital subtraction angiography alone</Intervention><Intervention>gemcitabine plus glycyrrhizin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Pancreatic &lt;b&gt;cancer&lt;/b&gt; patients would receive nano drug interventional therapy (Gemzar with glycyrrhizin Injection) or drug microspheres (HepaSphere Microspheres) interventional... Patients with other primary tumor except pancreatic &lt;b&gt;cancer&lt;/b&gt; History of coagulation disorders or anemia...18 to 80 years Karnofsky performance status&amp;gt; 60 Diagnosis of pancreatic &lt;b&gt;cancer&lt;/b&gt; based on histology or the current accepted radiological measures Classification tumor</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Nano Drug Interventional Therapy Using Digital Subtraction Angiography (DSA) for Pancreatic Carcinoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer - TNM Stage II pancreatic cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer - TNM Stage III pancreatic cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Niu, PhD</Name></ContactNames></Trial><Trial Id="80346"><Indications><Indication>Metastatic prostate cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glutamate carboxypeptidase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Neoplasm diagnostic agent</Action><Action>PET contrast agent</Action><Action>Radiodiagnostic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Intravenous formulation</Technology><Technology>Radiolabeling</Technology></Technologies><CompaniesCollaborator><Company>Prostate Cancer Foundation</Company><Company>Radiological Society of North America, US</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sidney Kimmel Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-19T00:00:00Z</DateChangeLast><DateEnd>2014-09-30T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>J1057</Identifier><Identifier>NA_00019359</Identifier><Identifier>NCT01417182</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>PET radiotracer (prostate cancer), Johns Hopkins University School of Medicine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age &amp;gt;/= 18 years Histological confirmation of prostate &lt;b&gt;cancer&lt;/b&gt; Radiological evidence of new or progressive metastatic disease demonstrated on anatomical imaging...Antonio, TX. [18F]-DCFBC uptake was found to be concordant with prostate &lt;b&gt;cancer&lt;/b&gt; metastasis as determined by conventional imaging modality. A total of 32 PET-positive sites...would determine the biodistribution, pharmacokinetics, and prostate specific tumor uptake in patients with metastatic prostate &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Biodistribution and Pharmacokinetic Study of [18F]-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>N-Acetyl-1-aspartylglutamic acid </BiomarkerName><BiomarkerName> Prostate-specific antigen </BiomarkerName><BiomarkerName> Standardized uptake value</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Steve Cho, MD</Name></ContactNames></Trial><Trial Id="37954"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HLA class I antigen A-33 alpha inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Gastrointestinal diagnostic agent</Action><Action>Neoplasm diagnostic agent</Action><Action>Radioimmunodiagnostic</Action><Action>Radiotherapeutic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intra-arterial formulation</Technology><Technology>Intravenous formulation</Technology></Technologies><CompaniesCollaborator><Company>Ludwig Institute for Cancer Research (US)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2004-02-29T00:00:00Z</DateStart><Identifiers><Identifier>03-124</Identifier><Identifier>ID LUD2001-011</Identifier><Identifier>NCT00199862</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>positron-emission tomography (PET) alone</Intervention><Intervention>radiolabelled-huA33 (colorectal cancer), Ludwig alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>single 4 mCi/10 mg iv dose of 124I-huA33 in patients with colorectal &lt;b&gt;cancer&lt;/b&gt;. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and in the...not included as colon &lt;b&gt;cancer&lt;/b&gt; is extremely rare in children Women of childbearing potential with confirmed negative pregnancy test The... The pu rpose of this open-label, pilot study is to determine if 124I-huA33 , can safely detect colorectal &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Antibodies</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of test modalities</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Laboratory Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Radio-Labeled huA33 Antibody in Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>184 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Steven Larson</Name><Name>Steven M Larson, MD</Name></ContactNames></Trial><Trial Id="265696"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Metastatic ovary cancer</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Caspase recruitment domain protein-15 stimulator</Action><Action>TLR-9 agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Caspase recruitment domain protein-15 stimulator</Action><Action>TLR-9 agonist</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Adjuvant</Action><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Anticancer</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Anticancer</Action><Action>Immunomodulator</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drug coating</Technology><Technology>Intravenous formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateStart>2017-12-08T00:00:00Z</DateStart><Identifiers><Identifier>I 277115</Identifier><Identifier>NCI-2016-00811</Identifier><Identifier>NCT02833506</Identifier><Identifier>P30CA016056</Identifier><Identifier>R01CA158318</Identifier></Identifiers><InterventionsControlDisplay><Intervention>MIS-416 plus recombinant NY-ESO-1 protein</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including MIS-416 , recombinant NY-ESO-1 protein , sirolimus</Intervention></InterventionsPrimaryDisplay><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated &lt;b&gt;cancer&lt;/b&gt; antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these...NY-ESO-1 protein with MIS-416 in treating patients stage II to IV ovarian, fallopian tube, or primary peritoneal &lt;b&gt;cancer&lt;/b&gt;. Primary objective: To determine the safety and feasibility of NY-ESO-1 protein with MIS-416 in combination with mammalian</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Sirolimus and Vaccine Therapy in Treating Patients With Stage II to IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIA ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIB ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIC ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIIA ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIIB ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IIIC ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with HLA positive disease</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-cancer/testis antigen 1 antibodies </BiomarkerName><BiomarkerName> CA-125 antigen </BiomarkerName><BiomarkerName> CD8-Positive T-Lymphocytes </BiomarkerName><BiomarkerName> Cancer/testis antigen 1 </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-08-15T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kunle Odunsi</Name></ContactNames></Trial><Trial Id="203550"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer hormone antagonist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>BC Cancer Agency</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-12-27T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER</Identifier><Identifier>NCT00816582</Identifier><Identifier>PET/CT</Identifier><Identifier>PET/CT BREAST</Identifier><Identifier>RECURRENT OR METASTATIC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>18F-FDG PET/CT alone</Intervention><Intervention>18F-fluoroestradiol alone</Intervention><Intervention>fulvestrant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>subject's &lt;b&gt;cancer&lt;/b&gt;. A 18F-FES PET/CT scan will be performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast &lt;b&gt;cancer&lt;/b&gt;. A 18F-FES PET/CT scan...predict clinical benefit (defined as complete response, partial response and stable disease &amp;gt;/= 6 months) to fulvestrant in post-menopausal women with recurrent or metastatic ER+ breast &lt;b&gt;cancer&lt;/b&gt; who are candidates for further hormonal therapy.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estrogen receptor </BiomarkerName><BiomarkerName> Progesterone receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>121 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Abdulwahab Al-tourah</Name><Name>Andrew Attwell</Name><Name>Barbara Czerkawski</Name><Name>Francois Benard</Name><Name>Sharon Allan</Name><Name>Stephen Chia, MD</Name><Name>Susan Ellard</Name><Name>Vanessa Bernstein</Name></ContactNames></Trial><Trial Id="76181"><Indications><Indication>Hormone refractory prostate cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>FGF-2 ligand inhibitor</Action><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>Ribosomal protein S6 kinase stimulator</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Canadian Cancer Trials Group</Company><Company>Cascadian Therapeutics Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>NCIC Clinical Trials Group</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-12-08T00:00:00Z</DateChangeLast><DateEnd>2015-11-30T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>I205</Identifier><Identifier>NCT01331083</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sonolisib (oral, cancer), Cascadian Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>with a history of other malignancies, except for adequately treated non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; or solid tumors curatively treated with no evidence of disease for &amp;gt;/= 3...luteinizing hormone-releasing hormone (LHRH) agonist must continue for those prostate &lt;b&gt;cancer&lt;/b&gt; patients already receiving this treatment at the time of enrollment. If...be made for low dose, non-myelosuppressive radiotherapy after consultation with National &lt;b&gt;Cancer&lt;/b&gt; Institute of Canada clinical trials group (NCIC CTG). Prior strontium</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of metastasis</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response (ORR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Castrate Resistant Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy</PatientSegment><PatientSegment>Prostate tumor - Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </BiomarkerName><BiomarkerName> Prostate-specific antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Kim Chi</Name><Name>Sebastien Hotte</Name></ContactNames></Trial><Trial Id="72634"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligosaccharide</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Tumor antigen therapeutic</Technology></Technologies><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-23T00:00:00Z</DateChangeLast><DateEnd>2017-03-15T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>09-184</Identifier><Identifier>NCT01248273</Identifier></Identifiers><IndicationsAdverse><Indication>Death</Indication><Indication>Fever</Indication><Indication>Hyperglycemia</Indication><Indication>Hypoglycemia</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>multivalent carbohydrate-based vaccine (cancer), Memorial Sloan-Kettering alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>26</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>other &lt;b&gt;cancer&lt;/b&gt; present within the last five years, or whose previous &lt;b&gt;cancer&lt;/b&gt; treatment contraindicated this protocol therapy are excluded. Non-melanoma skin cancers are an exception and will not exclude any patient Patients with a history of a seafood...effects, good and/or bad, it has, and to find out if the vaccine stimulates the immune system. The purpose of this study was to see if investigators would help the immune system to recognize that &lt;b&gt;cancer&lt;/b&gt; cells were not normal and would be removed.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer in First Remission</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with clear cell adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor - Subjects with mucinous adenocarcinoma of the ovaries</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Early/Localized Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Locally Advanced Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Stage III Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Stage IV Soft Tissue Sarcoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> CA-125 antigen </BiomarkerName><BiomarkerName> CD40 ligand </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>75 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David¬†Spriggs</Name><Name>Paul Sabbatini, MD</Name></ContactNames></Trial><Trial Id="258676"><Indications><Indication>Cancer</Indication><Indication>Ischemic stroke</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IIa antagonist</Action><Action>Factor IX antagonist</Action><Action>Factor VII antagonist</Action><Action>Factor X antagonist</Action><Action>Factor Xa antagonist</Action><Action>Low molecular weight heparin</Action><Action>Vitamin K epoxide reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiarrhythmic agent</Action><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Intravenous formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Samsung Medical Center (SMC)</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-05-25T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02743052</Identifier><Identifier>OASIS-CANCER</Identifier><Identifier>SMC 2016-02-104</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enoxaparin sodium alone</Intervention><Intervention>rivaroxaban alone</Intervention><Intervention>warfarin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>D-dimer levels Patients with stroke suspected to be caused by the tumor itself (ie, tumor emboli) or &lt;b&gt;cancer&lt;/b&gt; treatment (ie, chemotherapy-induced stroke)...onset &lt;b&gt;Cancer&lt;/b&gt; related stroke: active &lt;b&gt;cancer&lt;/b&gt; (diagnosis of &lt;b&gt;cancer&lt;/b&gt; within 6 months of stroke onset, any treatment for &lt;b&gt;cancer&lt;/b&gt; within the...biological markers for intravascular coagulopathy causing stroke and for monitoring the effects of anticoagulation therapy, in patients with active &lt;b&gt;cancer&lt;/b&gt; and stroke.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Stroke - Assessment of Blood Coagulation</EndpointIndex><EndpointIndex>Stroke - Assessment of Cerebrovascular Events - Assessment of cerebral ischemic lesions</EndpointIndex><EndpointIndex>Stroke - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Stroke - Assessment of Laboratory/Diagnostic Measures - D-dimer</EndpointIndex><EndpointIndex>Stroke - Assessment of Other Events - Assessment of neurological events</EndpointIndex><EndpointIndex>Stroke - Assessment of Recurrence of Stroke</EndpointIndex><EndpointIndex>Stroke - Assessment of Systemic Embolism - Assessment of venous thromboembolism</EndpointIndex><EndpointIndex>Stroke - Assessment of Thrombotic/Thromboembolic Events - Assessment of deep venous thrombosis</EndpointIndex><EndpointIndex>Stroke - Assessment of Thrombotic/Thromboembolic Events - Assessment of pulmonary embolism</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OASIS-CANCER: Anticoagulation in Cancer Related Stroke</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Cancer-related Symptoms</PatientSegment><PatientSegment>Solid tumor - Subjects with Advanced/Metastatic Solid Tumors</PatientSegment><PatientSegment>Solid tumor - Subjects with Relapsed/Recurrent Solid Tumors</PatientSegment><PatientSegment>Stroke - Subjects with Acute Stroke</PatientSegment><PatientSegment>Stroke - Subjects with Ischemic Stroke</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>D-dimer</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>110 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chin-Sang Chung, MD</Name><Name>Jong-Won Chung, MD</Name><Name>Jong-Won Chung, MD, MSc</Name><Name>Kwang Ho Lee, MD</Name><Name>Oh Young Bang, MD</Name><Name>Oh Young Bang, MD, PhD</Name></ContactNames></Trial><Trial Id="158427"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta-catenin inhibitor</Action><Action>DNA methyltransferase inhibitor</Action><Action>GM-CSF receptor agonist</Action><Action>Secreted frizzled related protein-2 stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Blood system agent</Action><Action>Synergist</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Gene expression regulation</Technology><Technology>Intradermal formulation</Technology><Technology>Prodrug</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Astex Therapeutics Ltd</Company><Company>Susan Cohan Colon Cancer Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sidney Kimmel Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-11T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>J13138</Identifier><Identifier>NA_00087578</Identifier><Identifier>NCT01966289</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>guadecitabine sodium alone</Intervention><Intervention>Variable regimens including cyclophosphamide , enistimagene setitucel + damistimagene matitucel , guadecitabine sodium</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>cells. Cohort 3: during each of the four cycles, patients will receive iv cyclophosphamide on day 1 at 200 mg/m2 and intradermal GVAX day 2 at 5(8) colon &lt;b&gt;cancer&lt;/b&gt; cells + 5(7) GM-CSF...days prior to receiving study drug Chemotherapy, radiation, hormonal, or biological &lt;b&gt;cancer&lt;/b&gt; therapy within 28 days prior to receiving study drug Pregnant or lactating...Documented &lt;b&gt;cancer&lt;/b&gt; of the colon or rectum who have received and are stable on first or second-line therapy regimens for metastatic colorectal &lt;b&gt;cancer&lt;/b&gt; Eastern Cooperative</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Tumor-Infiltrating Lymphocytes </BiomarkerName><BiomarkerName> Ubiquitin carboxyl-terminal hydrolase isozyme L1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>84 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Nilofer Azad, MD</Name></ContactNames></Trial><Trial Id="178656"><Indications><Indication>Metastatic bladder cancer</Indication><Indication>Metastatic pancreas cancer</Indication><Indication>Metastatic prostate cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Prostate stem cell antigen inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Imaging agent</Action><Action>Neoplasm diagnostic agent</Action><Action>Radiodiagnostic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Intravenous formulation</Technology><Technology>Radiolabeling</Technology></Technologies><CompaniesCollaborator><Company>ImaginAb Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Jonsson Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-01-06T00:00:00Z</DateEnd><DateStart>2013-08-22T00:00:00Z</DateStart><Identifiers><Identifier>13-000922</Identifier><Identifier>MNBD-PROT01</Identifier><Identifier>NCT02092948</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>124-iodine-labeled PSCA targeting minibody (cancer), ImaginAb alone</Intervention><Intervention>positron emission tomography alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>8</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>CT to look at the &lt;b&gt;cancer&lt;/b&gt; cells in your body that have taken up the study agent as well as to see their location in your body. Patients would receive...following laboratory results should be within the following limits within 4 weeks prior to study day 1: PSA&amp;gt; 5 (only for prostate &lt;b&gt;cancer&lt;/b&gt; patients) Absolute neutrophil...drug [124 I] PSCA-Minibody would be used for imaging prostate, pancreatic or bladder &lt;b&gt;cancer&lt;/b&gt; that has spread to the bones and soft tissues (eg, lymph nodes, lungs</Teaser><TrialCategories><Category>Diagnostic</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Metastasis</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Laboratory/Diagnostic Measures - Serum assessment</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Pancreas tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex><EndpointIndex>Pancreas tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Prostate tumor - Anthropometric Assessments</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Metastasis</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Renal Function</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Prostate tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CTCAE grading system</EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase I Study to Evaluate 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Metastatic Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Relapsed/Recurrent Bladder Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Relapsed/Recurrent Pancreatic cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects With Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-01-06T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alan Pantuck, MD</Name></ContactNames></Trial><Trial Id="77227"><Indications><Indication>Adenoma</Indication><Indication>Colorectal tumor</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Cyclooxygenase inhibitor</Action><Action>Ornithine decarboxylase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action><Action>Ornithine decarboxylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Cancer Prevention Pharmaceuticals Inc</Company><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Southwest Oncology Group</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-24T00:00:00Z</DateChangeLast><DateEnd>2029-07-31T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCI-2012-02067</Identifier><Identifier>NCT01349881</Identifier><Identifier>PACES</Identifier><Identifier>S0820</Identifier><Identifier>U10CA037429</Identifier></Identifiers><InterventionsControlDisplay><Intervention>eflornithine + sulindac (familial adenomatous polyposis/colon cancer), Cancer Prevention Pharmaceuticals alone</Intervention><Intervention>sulindac alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>eflornithine + sulindac (familial adenomatous polyposis/colon cancer), Cancer Prevention Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1340</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>of gastric/duodenal ulcer Known history of familial adenomatous polyposis, hereditary non-polyposis colorectal &lt;b&gt;cancer&lt;/b&gt; or inflammatory bowel disease Uncorrectable hearing loss &amp;gt;/=...skin &lt;b&gt;cancer&lt;/b&gt;, in situ cervical &lt;b&gt;cancer&lt;/b&gt;, or other &lt;b&gt;cancer&lt;/b&gt; for which the patient has been disease-free for &amp;gt; five... History of stages 0 to III colon &lt;b&gt;cancer&lt;/b&gt; with primary resection one year previously Post-operative colonoscopy and CT scans of chest, abdomen and pelvis showing</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - CRC Risk Factor Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Colorectal cancer incidence/prevalence and stage distribution</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PACES: Adenoma and Second Primary Prevention Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM Stage 0 Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM Stage I/Dukes A Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2025-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>196 Months</TrialDuration><NumberOfSites>1125</NumberOfSites><ContactNames><Name>Albert S. DeNittis</Name><Name>Allen S. Lim</Name><Name>Amitpal S. Johal</Name><Name>Andrew S. Delmas</Name><Name>Angela T. Alistar</Name><Name>Anita K. Gregory</Name><Name>Aqeel A. Gillani</Name><Name>Ari D. Baron</Name><Name>Arvinder S. Bir</Name><Name>Augusto C. Ochoa</Name><Name>Benjamin T. Marchello</Name><Name>Beverly J. Drucker</Name><Name>Blanche H. Mavromatis</Name><Name>Bret E. Friday</Name><Name>Bryan A. Faller</Name><Name>Burke J. Brooks</Name><Name>Carl J. Minniti</Name><Name>Carl W. Sharer</Name><Name>Carroll D. Scroggin</Name><Name>Chung-Tsen Hsueh</Name><Name>Dana Sparks, MAT</Name><Name>David A. Mullins</Name><Name>David M. King</Name><Name>Deborah W. Wilbur</Name><Name>Deirdre J. Cohen</Name><Name>Donald B. Wender</Name><Name>Donald J. Jurgens</Name><Name>Elise D. Cook</Name><Name>Eric M. Knoche</Name><Name>Gamini S. Soori</Name><Name>Gary E. Goodman</Name><Name>Han A. Koh</Name><Name>Howard A. Zaren</Name><Name>Howard M. Gross</Name><Name>Ira A. Oliff</Name><Name>Isoken Koko</Name><Name>James E. Clarkson</Name><Name>James E. Radford</Name><Name>James H. Feusner</Name><Name>January Fields-Meehan</Name><Name>Jason A Zell</Name><Name>Jason A. Zell</Name><Name>Jay W. Carlson</Name><Name>Jeffrey K. Giguere</Name><Name>Jeffrey L. Berenberg</Name><Name>Jennifer A. Dorth</Name><Name>John A. Ellerton</Name><Name>John A. Keech</Name><Name>John P. Kuebler</Name><Name>Joshua E. Melson</Name><Name>Joshua P. Raff</Name><Name>Kathleen J. Yost</Name><Name>Ke Ning</Name><Name>Keren Sturtz</Name><Name>Kiran K. Yalamanchili</Name><Name>Krista E. Evans</Name><Name>Kurt Oettel</Name><Name>Leon C. Hwang</Name><Name>Mandy D. Robertson</Name><Name>Mark F. Kozloff</Name><Name>Martin D. McCarter</Name><Name>Matthew L. Ryan</Name><Name>Mehmet S. Copur</Name><Name>Michal G. Rose</Name><Name>Mitchell Haut</Name><Name>Mokenge P. Malafa</Name><Name>Muhammad I. Moid</Name><Name>Nancy B. Kuemmerle</Name><Name>Panos Fidias</Name><Name>Patricia N. O'Kane, B.S.</Name><Name>Patrick J. Flynn</Name><Name>Philip E. Lammers</Name><Name>Philip J. Stella</Name><Name>Robert J. Behrens</Name><Name>Robin T. Zon</Name><Name>Sagila George</Name><Name>Sajid A. Khan</Name><Name>Salvatore A. Del Prete</Name><Name>Samantha A. Seaward</Name><Name>Shailja Roy</Name><Name>Shaker R. Dakhil</Name><Name>Shylendra B. Sreenivasappa</Name><Name>Site Public Contact</Name><Name>Sreedhar Katragadda</Name><Name>Stephen K. Williamson</Name><Name>Steven A. Akman</Name><Name>Steven R. Schuster</Name><Name>Stuart A. Krauss</Name><Name>Sukeshi P. Arora</Name><Name>Sunitha Vemulapalli</Name><Name>Syma Iqbal</Name><Name>Thomas J. Reid</Name><Name>Timothy D. Moore</Name><Name>Tomislav Dragovich</Name><Name>Vi K. Chiu</Name><Name>Wahid T. Hanna</Name><Name>Willard G. Andrews</Name><Name>William P. Fusselman</Name><Name>Yixing Jiang</Name></ContactNames></Trial><Trial Id="173466"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Dendritic cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Local formulation unspecified</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Abramson Cancer Center of the University of Pennsylvania</Company></CompaniesCollaborator><CompaniesSponsor><Company>H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-06T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2014-10-01T00:00:00Z</DateStart><Identifiers><Identifier>25113</Identifier><Identifier>818532</Identifier><Identifier>Adjuvant</Identifier><Identifier>MCC-18777</Identifier><Identifier>NCT02063724</Identifier><Identifier>NCT02110173</Identifier><Identifier>UPCC 25113</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HER-2/Neu Pulsed DC1 Vaccine (breast cancer), ImmunoRestoration alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Patients with HER-2 driven Invasive Breast &lt;b&gt;Cancer&lt;/b&gt; (IBC) at least stage IIIA with N2 following chemotherapy with/without trastuzumab or those with recurrence exclusive...Abramson &lt;b&gt;Cancer&lt;/b&gt; Center of the University of Pennsylvania and will be continued at H. Lee Moffitt &lt;b&gt;Cancer&lt;/b&gt; Center and Research...breast &lt;b&gt;cancer&lt;/b&gt; at least stage IIIA &amp;gt;/= N2 (four positive nodes) or have recurrent metastatic breast &lt;b&gt;cancer&lt;/b&gt; rendered NED by any means that</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Mammography</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Adjuvant: HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Others - Subjects with node positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment><PatientSegment>Breast tumor - Subjects with invasive breast cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Monocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>75 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Bonnie Ky</Name><Name>Brian Czerniecki, M.D., Ph.D.</Name><Name>Paul Zhang</Name><Name>Robert Roses</Name><Name>Rosemarie Mick</Name><Name>Susan Weinstein</Name></ContactNames></Trial><Trial Id="85269"><Indications><Indication>Fallopian tube cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peritoneal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF-1 agonist</Action><Action>Cancer testis antigen NY-ESO-1 modulator</Action><Action>GM-CSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiparkinsonian</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Hematopoietic stimulator</Action><Action>Immunostimulant</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Cancer Research Institute (CRI)</Company><Company>Roswell Park Comprehensive Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-02-18T00:00:00Z</DateChangeLast><DateEnd>2011-01-24T00:00:00Z</DateEnd><DateStart>2008-11-14T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000628730</Identifier><Identifier>LUD2007-005</Identifier><Identifier>NCT00803569</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous NY-ESO-1-targeting dendritic cell vaccine (cancer), Roswell Park Comprehensive Cancer Center plus sargramostim</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>as through hematology and chemistry laboratory testing and physical examinations. Efficacy was determined through tumor response evaluations, &lt;b&gt;cancer&lt;/b&gt; antigen (CA)-125 levels, and cellular and humoral immune responses (ie, NY-ESO-1-specific T cells...vitiligo Other malignancy within three years prior to entry into the study, except for treated non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; and cervical carcinoma in situ Known immunodeficiency or human immunodeficiency virus positivity Known allergy or history of life-threatening</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of adverse events as graded by CTCAE/CTC</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage II ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage III ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-01-24T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Kunle Odunsi, MD, PhD</Name></ContactNames></Trial><Trial Id="60044"><Indications><Indication>Hormone dependent prostate cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Anticancer</Action><Action>Immunostimulant</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Natural product</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-06T00:00:00Z</DateChangeLast><DateEnd>2008-06-01T00:00:00Z</DateEnd><DateStart>1999-09-30T00:00:00Z</DateStart><Identifiers><Identifier>99-056</Identifier><Identifier>MSKCC-99056</Identifier><Identifier>NCI-G00-1697</Identifier><Identifier>NCT00004929</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MUC2-KLH conjugate vaccine (prostate cancer), Memorial Sloan-Kettering alone</Intervention><Intervention>QS-21 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>T cell response against glycosylated MUC-2 in patients with progressive prostate &lt;b&gt;cancer&lt;/b&gt;; determine the safety of this treatment regimen in this patient population... Disease characteristics: Histologically confirmed prostate &lt;b&gt;cancer&lt;/b&gt; Disease progression with three or more rising PSA levels at least 2 weeks apart with greater...other active malignancy within the past five years except nonmelanoma skin &lt;b&gt;cancer&lt;/b&gt; No infection requiring antibiotics No seafood allergies No positive stool guaiac</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of antibody titers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of cellular response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response (ORR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of measurable disease response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vaccine Therapy Plus QS-21 in Treating Patients With Progressive Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>104 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Susan Slovin, MD, PhD</Name></ContactNames></Trial><Trial Id="101438"><Indications><Indication>Metastatic esophageal cancer</Indication><Indication>Metastatic stomach cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Placenta growth factor ligand inhibitor</Action><Action>VEGF-A ligand inhibitor</Action><Action>VEGF-B ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer protein kinase inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Metastasis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology><Technology>Receptor fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Dana-Farber Cancer Institute Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2017-07-26T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>12-401</Identifier><Identifier>NCT01747551</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-Fluorouracil , aflibercept (intravenous, cancer), Regeneron/Sanofi , folinic acid , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>64</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>were eligible. Many of these tests and procedures were likely to be part of regular &lt;b&gt;cancer&lt;/b&gt; care and may be done even if it turns out that patients do not take part...carcinoma in situ or prostatic intraepithelial neoplasia without evidence of prostate &lt;b&gt;cancer&lt;/b&gt; Uncontrolled non-malignant illness Uncontrolled psychiatric illness...received any prior chemotherapy, investigative or biologic agents for esophagogastric &lt;b&gt;cancer&lt;/b&gt; except in the neoadjuvant or adjuvant setting Any major surgery must</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Esophagus tumor - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Oncogenes/Oncoproteins - Assessment of growth factors and receptors</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of radiographic response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>FOLFOX +/- Ziv-Aflibercept For Esophageal And Gastric Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Esophagus tumor - Subjects with Adenocarcinoma of Esophagus</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Gastro-esophageal Junction Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Locally Advanced Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage III Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Unresectable Esophageal Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Locally Advanced Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage III Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage IV Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Unresectable Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with adenocarcinoma of the gastroesophageal junction</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Mothers against decapentaplegic homolog 2 </BiomarkerName><BiomarkerName> Mothers against decapentaplegic homolog 3 </BiomarkerName><BiomarkerName> Neuropilin-1 </BiomarkerName><BiomarkerName> Neuropilin-2 </BiomarkerName><BiomarkerName> Pappalysin-1 </BiomarkerName><BiomarkerName> Transforming growth factor beta 1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factor A </BiomarkerName><BiomarkerName> Vascular endothelial growth factor receptor-2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-11-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Peter Enzinger, MD</Name></ContactNames></Trial><Trial Id="92212"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>p53 tumor suppressor protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>National Cancer Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-10T00:00:00Z</DateChangeLast><DateEnd>2005-12-31T00:00:00Z</DateEnd><DateStart>2000-08-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000067284</Identifier><Identifier>NCI-99-C-0142</Identifier><Identifier>NCI-T96-0045</Identifier><Identifier>NCT00001829</Identifier><Identifier>NCT00019929</Identifier><Identifier>VU-VCC-THO-9814</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the overall survival in patients with locally advanced non-small cell lung &lt;b&gt;cancer&lt;/b&gt; immunized with adjuvant mutant p53 peptide pulsed dendritic cell vaccine after...characteristics: Histologically confirmed stage III A or III B non-small cell lung &lt;b&gt;cancer&lt;/b&gt; (NSCLC) with one of the following p53 mutations: Point mutation altering...efficacy of mutant p53 peptide pulsed dendritic cell vaccine therapy given after standard therapy in treating patients with stage III non-small cell lung &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of immunological markers</EndpointIndex></EndpointIndex><TitleDisplay>Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>64 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Jay A. Berzofsky, MD, PhD</Name></ContactNames></Trial><Trial Id="250457"><Indications><Indication>Adenocarcinoma</Indication><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Bcl-2 protein modulator</Action><Action>Caspase-3 stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Lipid</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Berg Pharma LLC</Company></CompaniesSponsor><Countries><Country>US</Country><Country>UK</Country></Countries><DateChangeLast>2019-04-02T00:00:00Z</DateChangeLast><DateEnd>2019-01-31T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>BPM31510IV-05</Identifier><Identifier>NCT02650804</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ubidecarenone (iv, cancer), Berg Pharma alone</Intervention><Intervention>gemcitabine plus ubidecarenone (iv, cancer), Berg Pharma</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>2 cycles (8 weeks). Toxicity would be graded according to National &lt;b&gt;Cancer&lt;/b&gt; Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.02). Assessments...1 &lt;b&gt;cancer&lt;/b&gt;, cured basal cell carcinoma, superficial bladder &lt;b&gt;cancer&lt;/b&gt;, breast ductal carcinoma in situ (DCIS), or...intravenous infusion as&amp;nbsp;a&amp;nbsp;monotherapy&amp;nbsp;or&amp;nbsp;in&amp;nbsp;combination with gemcitabine in advanced pancreatic &lt;b&gt;cancer&lt;/b&gt; patients as second or third line therapy [ 1756656 ], [ 1960338 ], [ 1999054</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Biomarkers - CA19-9 biomarker</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BPM-31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Adenocarcinoma of Pancreas</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CA19-9 antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Angela Alistar, MD</Name><Name>Anna Niewiarowska, MD</Name><Name>David Propper, MD</Name><Name>Dr David Propper</Name><Name>James Strauss, MD</Name><Name>Madappa Kundranda, MD, PhD</Name><Name>Manuel Hidalgo Medina, MD</Name><Name>Paul Ritch, MD</Name><Name>Ramesh K Ramanathan, MD</Name><Name>Ramesh Ramanathan, MD</Name><Name>Roopinder Gillmore, MD</Name><Name>Sant P Chawla, MD</Name><Name>Thomas Evans, MD</Name></ContactNames></Trial><Trial Id="261275"><Indications><Indication>Advanced solid tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase alpha inhibitor</Action><Action>DNA primase inhibitor</Action><Action>Interleukin-2 ligand</Action><Action>Programmed cell death protein 1 inhibitor</Action><Action>Ribonucleotide reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer hormone</Action><Action>Anticancer monoclonal antibody</Action><Action>Antiviral</Action><Action>DNA synthesis inhibitor</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Film coating</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intradermal formulation</Technology><Technology>Intraperitoneal formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Jonsson Comprehensive Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-03T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2017-06-30T00:00:00Z</DateStart><Identifiers><Identifier>15-001433</Identifier><Identifier>15-001433</Identifier><Identifier>NCI-2016-00201</Identifier><Identifier>NCT02775292</Identifier><Identifier>NYM</Identifier><Identifier>P30CA016042</Identifier><Identifier>RIBAS NYESO + NIVOLUMAB CANCER</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>positron emission tomography alone</Intervention><Intervention>Variable regimens including NY-ESO-1 peptide-pulsed autologous dendritic cell vaccine (solid tumor), NCI , NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL , aldesleukin , cyclophosphamide , fludarabine , nivolumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Previously known hypersensitivity to any of the agents used in this study Received systemic treatment for &lt;b&gt;cancer&lt;/b&gt;, including immunotherapy, within 1 month prior to initiation of dosing within this protocol History of, or significant evidence...nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the &lt;b&gt;cancer&lt;/b&gt;-testes antigen NY-ESO-1 gene and have spread from where it started to nearby tissue or lymph nodes (locally advanced</Teaser><TrialCategories><Category>Biological</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Solid tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Solid tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NYM: Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1</TitleDisplay><PatientSegmentTerms><PatientSegment>Solid tumor - Subjects with Advanced/Metastatic Solid Tumors</PatientSegment><PatientSegment>Solid tumor - Subjects with Locally Advanced Solid Tumors</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cancer/testis antigen 1 </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Standardized uptake value </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antoni Ribas</Name><Name>Siwen Hu-Lieskovan</Name></ContactNames></Trial><Trial Id="41000"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Ribonucleotide reductase M2 subunit inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>HIV replication inhibitor</Action><Action>Iron chelator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cancer Therapeutics Research Group</Company></CompaniesSponsor><Countries><Country>South Korea</Country><Country>Australia</Country><Country>Singapore</Country><Country>Hong Kong</Country></Countries><DateChangeLast>2017-02-10T00:00:00Z</DateChangeLast><DateEnd>2008-01-31T00:00:00Z</DateEnd><DateStart>2004-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000350313</Identifier><Identifier>CTRG-LUN012</Identifier><Identifier>NCI-6256</Identifier><Identifier>NCT00077415</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspnea</Indication><Indication>Hypoxia</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>gemcitabine alone</Intervention><Intervention>Variable regimens including Triapine (intravenous, cancer), Ology Bioservices , gemcitabine , gemcitabine + Triapine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>31</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>response rate in patients with stage III or IV recurrent non-small cell lung &lt;b&gt;cancer&lt;/b&gt; treated with 3-AP (Triapine) and gemcitabine as second-line therapy. The secondary... Disease characteristics: Histologically or cytologically confirmed non-small cell lung &lt;b&gt;cancer&lt;/b&gt; (NSCLC) Stage III or IV disease One of the following cellular types...except completely treated carcinoma in situ of the cervix or nonmelanoma skin &lt;b&gt;cancer&lt;/b&gt; No prior allergic reaction attributed to compounds of similar chemical or biological</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Brigette Ma</Name></ContactNames></Trial><Trial Id="43369"><Indications><Indication>Hormone refractory prostate cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Tubulin binding agent</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Microtubule stabilizer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Theradex Ltd</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-04-21T00:00:00Z</DateChangeLast><DateStart>2001-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000068930</Identifier><Identifier>JHOC-01011003</Identifier><Identifier>NCT00024414</Identifier><Identifier>PROTARGA-P01-00-04</Identifier><Identifier>THERADEX-P01-00-04</Identifier></Identifiers><IndicationsAdverse><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>paclitaxel (DHA-linked, cancer), Luitpold alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>time to disease progression in patients with metastatic hormone-refractory prostate &lt;b&gt;cancer&lt;/b&gt; treated with Taxoprexin . Determine the overall survival of patients...would be accrued for this study. A total of 36 patients with hormone refractory prostate &lt;b&gt;cancer&lt;/b&gt; would administered Taxoprexin (1100 or 900 mg/m2) as a 2-h iv infusion...skin &lt;b&gt;cancer&lt;/b&gt;; or other &lt;b&gt;cancer&lt;/b&gt; curatively treated with surgery alone that has not recurred for</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response (ORR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Prostate tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Castrate Resistant Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy</PatientSegment><PatientSegment>Prostate tumor - Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Prostate-specific antigen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>8</NumberOfSites><ContactNames><Name>Michael A. Carducci</Name></ContactNames></Trial><Trial Id="84259"><Indications><Indication>Diarrhea</Indication></Indications><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>MD Anderson Cancer Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-08T00:00:00Z</DateChangeLast><DateStart>2009-02-28T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000612205</Identifier><Identifier>MDA-2008-0005</Identifier><Identifier>MDA-2008-0005</Identifier><Identifier>NCT00748215</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>CASAD (cancer therapy induced diarrhea), Salient Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>incidence of grade 3/4 diarrhea in patients with metastatic colorectal &lt;b&gt;cancer&lt;/b&gt; receiving an irinotecan -based chemotherapy regimen. Secondary objectives were: To... Disease characteristics: Diagnosis of colorectal &lt;b&gt;cancer&lt;/b&gt;: Metastatic disease Scheduled to receive irinotecan hydrochloride alone or in combination with fluorouracil...placebo in treating and preventing diarrhea in patients with metastatic colorectal &lt;b&gt;cancer&lt;/b&gt; receiving irinotecan . By February 2012, 98 patients were enrolled [ 1270392</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Symptoms - MD Anderson symptom inventory</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Assessment of premature withdrawals</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Change in burden of illness and treatment over time</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Clinical Response - Assessment of Stool Frequency</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Treatment Induced Diarrhea - Assessment of chemotherapy induced diarrhoea</EndpointIndex><EndpointIndex>Diarrhea - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Quality of Life (QOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Gastrointestinal Complications</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>2</NumberOfSites><ContactNames><Name>Brian K. Kee, MD</Name><Name>Michael J. Fisch, MD, MPH, FACP</Name></ContactNames></Trial><Trial Id="39878"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>GCSF receptor agonist</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>DNA intercalator</Action><Action>Hematopoietic stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>DNA technology</Technology><Technology>Infusion</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Liposome formulation injectable</Technology><Technology>Liquid formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Duke University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-04-30T00:00:00Z</DateEnd><DateStart>2006-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000482411</Identifier><Identifier>DUMC-06068</Identifier><Identifier>DUMC-6883-06-2R1</Identifier><Identifier>NCT00346229</Identifier><Identifier>Pro00014340</Identifier></Identifiers><IndicationsAdverse><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including ThermoDox + pegfilgrastim + filgrastim , doxorubicin (heat-sensitive liposomes, cancer), Celsion , filgrastim , pegfilgrastim</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>29</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>breast &lt;b&gt;cancer&lt;/b&gt; chest wall recurrence (CWR) were presented at the 36th Annual CTRC-AACR San Antonio Breast &lt;b&gt;Cancer&lt;/b&gt; Symposium, in San Antonio, TX...in combination with local-regional hyperthermia in women with locally recurrent breast &lt;b&gt;cancer&lt;/b&gt;. Determine the pharmacokinetic profile of ThermoDox when used in multiple-course...order to be eligible Prior skin changes consistent with inflammatory breast &lt;b&gt;cancer&lt;/b&gt; are allowed Distant metastasis (excluding known brain metastases) allowed No</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of apoptosis</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Inflammatory Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kimberly Blackwell</Name><Name>Kimberly L. Blackwell, MD</Name></ContactNames></Trial></SearchResults></trialResultsOutput>